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   1.INTRODUCTION 
 
1.1. Oral drug delivery system:     (Banker G.S. and Rhodes C.T., 2009; Chein Y.W., 
2009; http://www.pharmainfo.net)    
Oral route has been the commonly adopted and most convenient route for the 
drug delivery. Oral route of administration has been received more attention in the 
pharmaceutical field, because of the more flexibility in the designing of dosage form 
than drug delivery design for other routes. The oral drug delivery depends on various 
factors such as type of delivery system, the disease being treated, the patient, the 
length of the therapy and the properties of the drug. Most of the oral controlled drug 
delivery systems (OCDDS) relay on diffusion, dissolution, or combination of both 
mechanisms, to release the drug in a controlled manner to the gastro intestinal tract 
(GIT). The physico-chemical properties include crystal nature, solubility, partition 
coefficient, intrinsic dissolution, etc. dosage form characteristics are controlled and 
optimized with respect to the physico-chemical properties of the drug and relevant GI 
environmental factors. Other factors need to be considered are diseased state, the 
patient compliance & length of therapy. The goal of targeted oral drug delivery 
systems is to achieve better therapeutic success compared to conventional dosage 
form of the same drug. This could be achieved by improving the pharmacokinetic 
profile, patient convenience and compliance in therapy. 
Oral route of drug delivery has been known for decades as the most to a wide 
extent used route of administration among all the routes that have been travel through 
to learn about it the systemic delivery of drugs via various pharmaceutical 
manufactured products of various dosage forms.  
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Oral route of administration has been used as either conventional or novel 
drug delivery system. There are many merits are there for this, not the least of which 
would include willingness to accept by the patient and facility of administration. 
Types of sustained release system employed for oral route of administration include 
virtually every at the present time now the theoretical mechanism for such 
application. This is because the manufacturing of dosage form is more flexibility, 
since constraint, such as sterility problem and potential damage at the site of 
administration are minimized. Because of this, it is easy to development of different 
types of dosage forms by customary those developed for oral route of administration 
as initial examples. 
    Regarding orally administered drugs, targeting is not a primary concern, and it 
is usually done on purpose for active component to permeate to the blood circulation 
and permeation through the other body tissue (the obvious exception being 
medication intended for local gastrointestinal tissue treatment). For this justification, 
most system employed the sustained release variety. 
Concentration of drug level it will increasing the rate absorption region and 
also, increase circulating blood levels, which in turn to raise to greater concentration 
of active content at the site of action. 
1.2. Drawbacks of Conventional Dosage Forms:  (Brahmankar D.M. and Jaiswal 
S.B., 2009; Shalin A. Modi, et al., 2011) 
1. Poor patient compliance, increased chances of missing the dose of a drug 
with short half-life for which frequent administration is necessary. 
2. The unavoidable fluctuations of drug concentration may lead to under 
medication or over medication. 
Lamivudine Sustained Release Matrix Tablets                  INTRODUCTION 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur.  3 
 
3. A typical peak-valley plasma concentration time profile is obtained which 
makes attainment of steady-state condition difficult. 
4. The fluctuations in drug levels may lead to precipitation of adverse effects 
especially of a drug with small Therapeutic Index (TI) whenever over medication 
occur. 
1.3. Sustained release drug delivery system:  (Banker G.S. and Rhodes C.T., 2009; 
http://www.pharmainfo.net) 
Over past 30 year as the expanse and complication involved in marketing new 
drug entities have increased, with concomitant recognition of the therapeutic 
advantages of controlled drug delivery, greater attention has been focused on 
development of sustained or controlled release drug delivery systems. There are 
several reasons for the attractiveness of these dosage forms. It is generally recognized 
that for many disease states, a substantial number of therapeutically effective 
compounds already exist.  
The effectiveness of these drugs, however, is often limited by side effects or 
the necessity to administer the compound in a clinical setting, the goal in designing 
sustained or controlled delivery system is to reduce the frequency of dosing or to 
increase effectiveness of the drug by localization at the site of action, reducing the 
dose required, or providing uniform drug delivery. Sustained release constitutes any 
dosage form that provides medication over and extended time. Controlled release, 
however, denotes that the system is able to provide some actual therapeutic control, 
whether this is of a temporal nature, spatial nature or both.  
This correctly suggests that there are sustain release system that cannot be 
considered controlled release system. In general, the goal of a sustained release 
dosage form is to maintain therapeutic blood or tissue levels of drug for an extended 
Lamivudine Sustained Release Matrix Tablets                  INTRODUCTION 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur.  4 
 
period this is usually accomplished by attempting to obtain zero-order release from 
the dosage form; zero-order release constitutes drug release from the dosage form. 
Sustained release systems generally do not attain this type of release and provides 
drug is a slow first order fashion. In recent year sustained release dosage forms 
continue to draw attention in the search for improved patient compliance and 
decreased incidence of adverse drug reactions. Sustained release technology is 
relatively cow field and as a consequence, research in the field has been extremely 
fertile and has produced many discoveries.  
Sustained release, sustained action, prolonged action controlled release, 
extended action, timed release, depot and repository dosage forms are terms used to 
identify drug delivery system that are designed to achieve or prolonged therapeutic 
effect by continuously releasing medication over an extended period of time after 
administration of a single dose. 
 
Figure 1.1: Plasma concentration versus time profile from conventional dosage and     
                   doses of sustained and controlled delivery formulation. 
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Systems that are designed as prolonged release can also be considered as 
attempts at achieving sustained-release delivery. Repeat action tablets are an 
alternative method of sustained release in which multiple doses of drug are contained 
within a dosage form, and each dosage is related to a periodic interval. Delayed 
release systems, in contrast may not be sustaining, science often function of these 
dosage forms is to maintain the drug within the dosage form for some time before 
release. Commonly the release rate of drug is not altered and does not result in 
sustained delivery once drug release has begun.  
Successful fabrication of sustained release products is usually difficult & and 
involves consideration of physicochemical properties of drug, pharmacokinetic 
behavior of drug, route of administration, disease state to be treated and, most 
importantly, placement of the drug in dosage form total will provide the desired 
temporal and spatial delivery pattern for the drug.  
The slow first order release obtained by a sustained release pre parathion is 
generally achieved by the release of the drug from a dosage form. In some cases in 
some cases, this achieved by making slow the release of drug from a dosage form. In 
some cases, this is accomplished by a continuous release process.  
1.3.1. Potential advantages of Sustained release drug delivery system:  
(http://www.pharma info.net) 
1. Patient compliance due to reduction in the frequency of designing. 
2. Employ minimum drug. 
3. Minimize or eliminates local and systemic side effects. 
4. Obtain less potentiating or deduction in drug activity with chronic use. 
5. Minimize drug accumulation with chromic dosing. 
6. Improves efficacy in treatment. 
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7. Cure or control confirm more promptly. 
8. Improve control of condition i.e. reduce fluctuation in drug level. 
9. Improve bioavailability of same drugs. 
10. Make use of special effects, e.g. sustained release aspect for morning relief of    
arthritis by dosing before bedtime. 
1.3.2. Disadvantages of Sustained release drug delivery system:    (http: //www. 
pharmainfo.net)  
1.   They are costly. 
2.   Unpredictable and often poor in-vitro in-vivo correlations, dose dumping,        
      reduced potential for dosage adjustment and increased potential first pass    
      clearance. 
3.   Poor systemic availability in general. 
4. Effective drug release period is influenced and limited by GI residence time. 
1.3.3. Rationale of sustained release drug delivery system: (Ansel H.C., 2009; Vyas 
S.P and Khar R.K., 2002) 
 To optimizing the factor such as pharmacokinetic, pharmacodynamic and 
biopharmaceutical these are the rationale of sustained release dosage form, these 
properties of active ingredient in such a type its maximum reducing the adverse effect 
and controlling disease growth condition in short time period by loading less quantity 
of drug, when we are administered in the suitable route. Many drugs are longer action 
because half life and only need for once day dosing so these type of drug not for 
sustained or controlled release tablet to give therapeutic effect in blood and this nature 
of drug we can be manufacturing in immediate release tablet as like conventional 
tablet. However, some drugs are not long action and need multiple daily dosing to 
obtain the therapeutic results.  
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 Multiple daily dosing is inconvenient for the patient, chance of missed doses, 
made up doses and non compliance with the regimen. When the conventional tablet 
which may causes variation of plasma level peaks and valley associated with the 
using of each dose. However, when a dose should not be administering such a manner 
because the obtaining result like peaks and valley give the less action of therapy. For 
example if a dosage form is administered short time interval, minimum toxic 
concentration of drug may be reached, with toxic side effect can occur. If doses are 
missed or forgetted, the administered drug goes to sub therapeutic levels on those 
below the minimum effective concentration (MEC) may result, so there is no use to 
the patient. 
1.3.4. Designing sustained-release drug delivery system:       (Shalin A. Modi, et al., 
2011) 
 Most of the orally administered drugs, targeting is not a primary concern and it 
is usually intended for drugs to penetrate to the general circulation and perfuse to 
other body tissues. For this reason, most systems employed are of the sustained 
release variety. It is assumed that increasing concentration at the absorption site will 
increase circulating blood levels, which in turn, promotes greater concentration of 
drug at the site of action. If toxicity is not an issue, therapeutic levels can thus be 
extended. In essence, drug delivery by these systems usually depends on release from 
some type of dosage form, permeation through biological milieu and absorption 
through an epithelial membrane to the blood. There are a variety of both 
physicochemical and biological factors that come into play in the design of such 
system.  
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1.3.5. Factors Affecting Sustained Release Dosage Forms:   (Chein Y.W., 2009; 
http://www.pharmainfo.net) 
1.3.5.1. Physicochemical properties of drug: 
a) Dose Size: 
If an oral product has a dose size greater that 0.5gm it is a poor candidate for 
sustained release system, Since addition of sustaining dose and  possibly the 
sustaining mechanism will, in most cases generates a substantial volume product that 
unacceptably large.  
b) Aqueous Solubility:  
Most of drugs are weak acids or bases, since the unchanged form of a drug 
preferentially permeates across lipid membranes drugs aqueous solubility will 
generally be decreased by conversion to an unchanged form for drugs with low water 
solubility will be difficult to incorporate into sustained release mechanism. The lower 
limit on solubility for such product has been reported 0.1mg/ml. drugs with great 
water solubility are equally difficult to incorporate in to sustained release system. pH 
dependent solubility, particularly in the physiological pH range, would be another 
problem because of the variation in pH throughout the GI tract and hence variation in 
dissolution rate.  
c) Partition Coefficient: 
Partition coefficient is generally defined as the fraction of drug in an oil phase 
to that of an adjacent aqueous phase. Accordingly compounds with relatively high 
partition coefficient are predominantly lipid soluble and consequently have very law 
aqueous solubility. Compounds with very law partition coefficients will have 
difficulty in penetrating membranes resulting poor bioavailability.  
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Figure 1.2: Typical relationship between drug activity and partition coefficient K. 
d) Dissociation constant (pka):  
The relationship between dissociation constant of compound and absorptive 
environment. Presenting drug in an unchanged form is adventitious for drug 
permeation but solubility decrease as the drug is in unchanged form.  
e) Drug Stability:  
Orally administered drugs can be subject to both acid base hydrolysis and 
enzymatic degradation. Degradation will proceed at the reduced rate for drugs in the 
solid state, for drugs that are unstable in stomach, systems that prolong delivery ever 
the entire course of transit in GI tract are beneficial. Compounds that are unstable in 
the small intestine may demonstrate decreased bioavailability when administered 
form a sustaining dosage from. This is because more drug is delivered in small 
intestine and hence subject to degradation.  
f) Molecular size and diffusivity: 
The ability of drug to diffuse through membrane it‟s so called diffusivity & 
diffusion coefficient is function of molecular size (or molecular weight). Generally, 
values of diffusion coefficient for intermediate molecular weight drugs, through 
flexible polymer range from 10-8 to 10-9 cm
2
 / sec. with values on the order of 10-8 
being most common for drugs with molecular weight greater than 500, the diffusion 
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coefficient  in many polymers frequently are so small that they are difficult to 
quantify i.e. less than 16-12 cm
2
/sec.  Thus high molecular weight drugs and / or 
polymeric drugs should be expected to display very slow release kinetics in sustained 
release device using diffusion through polymer membrane.  
g) Protein binding: 
It is well known that many drugs bind to plasma proteins with a concomitant 
influence on the duration of drug action. Since blood proteins are for the most part re-
circulated and not eliminated, drug Protein binding can serve as a depot for drug 
producing a prolonged release profile, especially if a high degree of drug binding 
occurs.  
Extensive binding to plasma proteins will be evidenced by a long half life of 
elimination for drugs and such drugs generally most require a sustained release 
dosage form. However drugs that exhibit high degree of binding to plasma proteins 
also might bind to bio-polymers in GI tract which could have influence on sustained 
drug delivery.  The presence of hydrophobic moiety on drug molecule also increases 
the binding potential.  
1.3.5.2. Biological factors: 
a) Biological Half Life: 
The usual goal of an oral sustained release product is to maintain therapeutic 
blood levels over an extended period. To action this, drug must enter in the circulation 
of approximately the same rate of which it is eliminated. The elimination rate is 
quantitatively described by half-life (t1/2). Therapeutic compounds with short half 
lives are excellent candidates for sustained release preparations. Since this can reduce 
dosing frequency. In general drugs with half-lives shorter than 3hrs are poor 
candidates of sustained release dosage forms of dose size will increase as well as 
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compounds with long half lives, more than 8 hrs are also not used in sustained release 
forms because their effect is already sustained.  
b) Absorption: 
The rate, extent and uniformity of absorption of a drug are important factors 
when considered its formulation into a sustained release system. As the rate limiting 
step in drug delivery from a sustained-release system is its release from a dosage 
form, rather than absorption. Rapid rate of absorption of drug, relative to its release is 
essential if the system is to be successful. It we assume that transit time of drug must 
in the absorptive areas of the GI tract is about 8-12 hrs. The maximum half life for 
absorption should be approximately 3-4 hrs. Otherwise device will pass out of 
potential absorption regions before drug release is complete.  
c) Distribution: 
The distribution of drugs into tissues can be important factor in the overall 
drug elimination kinetics. Since it not only lowers the concentration of circulating 
drug but it also can be rate limiting in its equilibrium with blood and extra vascular 
tissue, consequently apparent volume  of distribution assumes different values 
depending on time course of drug disposition. For design of sustained/ controlled 
release products, one must have information of disposition of drug.  
d) Metabolism: 
Drugs that are significantly metabolized before absorption, either in lumen or 
the tissue of the intestine, can show decreased bioavailability from slower-releasing 
dosage forms. Most intestinal wall enzymes systems are saturable. As drug is released 
at a slower rate to these regions less total drug is presented to the enzymatic. Process 
device a specific period, allowing more complete conversion of the drug to its 
metabolite. 
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e) Side effects: 
 The incidence of side effect of a drug is depends on its therapeutic 
concentration level in blood. It can be remedy by the drug concentration level is 
controlled at which timing that drug exists in blood after administration. Toxic effect 
of a drug is expected above the maximum effective range level and fall in the 
therapeutic effect if a drug below the level of minimum effective range. So the above 
problem we can solve by making sustained release preparation. 
f) Margin of safety:
 
 Therapeutic index of a drug is very important for either sustained or controlled 
release delivery system. Its value only desired the margin of safety. Therapeutic index 
value it has been longer means excellent for preparation of sustained release tablet. 
Narrow therapeutic index of some drug precise to release the active content in 
therapeutic safe and effective range. Some drug like cardiac glycosides that 
therapeutic index value is very small, so it‟s not used for sustained release delivery 
system.   
              Therapeutic index = TD50 ∕ ED50 
Where, TD50 - Median toxic dose 
             ED50 - Median effective dose. 
1.4. Oral controlled and sustained release systems:                    (Chein Y.W., 2009; 
http://www.pharmainfo.net; Shalin A. Modi, et al., 2011) 
The controlled release systems for oral use are mostly solids and based on 
dissolution, diffusion or a combination of both mechanisms in the control of release 
rate of drug. Depending upon the manner of drug release, these systems are classified 
as follows: 
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1.4.1. Continuous release systems: 
These systems release the drug for a prolonged period of time along the entire 
length of gastrointestinal tract with normal transit of the dosage form. The various 
systems under this category are as follow, 
A. Dissolution controlled release systems 
B. Diffusion controlled release systems 
C. Dissolution and diffusion controlled release systems 
D. Ion exchange resin- drug complexes 
E. pH dependent formulation 
F. Osmotic pressure controlled systems 
A. Dissolution controlled release systems: 
These types of systems are easiest to design. The drug present in such system 
may be the one: 
 With inherently slow dissolution rate e.g. Griseofulvin and Digoxin. 
 That produces slow dissolving forms, when it comes in contact with GI        
             fluids. 
 Having high aqueous solubility and dissolution rate. 
Drugs having high aqueous solubility and dissolution rate, shows challenge in 
controlling their dissolution rate. Dissolution-controlled release can be obtained by 
slowing the dissolution rate of a drug in the GI medium, incorporating the drug in an 
insoluble polymer and coating drug particles or granules with polymeric materials of 
varying thickness. The rate limiting step for dissolution of a drug is the diffusion 
across the aqueous boundary layer. The solubility of the drug provides the source of 
energy for drug release, which is countered by the stagnant-fluid diffusional boundary 
layer. The rate of dissolution (dm/dt) can be approximated by below equation.  
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Dm/dt = ADS/h 
Where, S = Aqueous solubility of the drug. 
            A = Surface area of the dissolving particle or tablet. 
            D = Diffusivity of the drug and 
            h = Thickness of the boundary layer. 
a) Matrix (or monolithic) dissolution controlled systems: 
As the drug is homogeneously dispersed throughout the rate controlling 
medium, this system is also called as monolith system. It is very common and 
employs waxes such as bees wax, carnauba wax which control the drug release rate 
by controlling the rate of dissolution fluid penetration into the matrix by altering the 
porosity of tablet, decreasing its wettability or by itself getting dissolved at a slower 
rate. The drug release is often first order from such matrices. 
b) Reservoir (Encapsulation) dissolution controlled systems: 
In this type, the drug particles are coated or encapsulated by one of the several 
microencapsulation techniques with slowly dissolving materials like cellulose and 
polyethylene glycol. The dissolution rate of coat depends upon the solubility and 
thickness of the coating. 
B. Diffusion controlled systems: 
The basic mechanism of drug release from these two systems is fundamentally 
different besides these simple systems, combination of reservoir and monolithic 
systems also exist in practice.Diffusion systems are characterized by release rate of 
drug is dependent on its diffusion through inert water insoluble membrane barrier.  
There are basically two types of diffusion devices.  
a) Reservoir devices    
b) Matrix devices  
Lamivudine Sustained Release Matrix Tablets                  INTRODUCTION 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur.  15 
 
a) Reservoir Devices: 
Reservoir Devices are those in which a core of drug is surrounded by 
polymeric membrane. The nature of membrane determines the rate of release of drug 
from system. The process of diffusion is generally described by a series of equations 
governed by Fick‟s first law of diffusion.  
J = -D (DC/ DX)……. (1) 
Where, „J‟ is the flux of drug across the membrane given in units of amount / area 
time.  
„D‟ is diffusion coefficient of drug in membrane in units of area / time. This is 
reflecting to drug molecule‟s ability to diffuse through the solvent and is dependent 
on the factors as molecular size and charge.  
„dc/dt‟ represents rate of change in concentration C relative to a distance X in 
the membrane.  
The law states that amount of drug passing across a unit area, is proportional 
to the concentration difference across that plane.  
 
Figure 1.3: Schematic representation of reservoir diffusion device Cm (o), and Cm                                                  
                  (d) represent concentration of drug inside surfaces of membrane and C (o)        
                  & C(d) represents concentration in adjacent  regions.  
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If it is assumed that the drug on the both side of membrane is in equilibrium 
with its respective membrane surface which in equilibrium between the membrane 
surfaces and their bathing solutions as shown in Figure. Therefore the concentration 
just inside the membrane surface can be related to the concentration in the adjacent 
region by following expression.  
K = Cm (o) / C(d)      at  X = o                                  (2) 
K = Cm (d) / C(d)     at  X = d                                  (3) 
Where K = partition coefficient.  
If we consider K & D are constants then equation (1) becomes,  
J = D K C/d                                                            (4) 
Where c is the concentration difference across the membrane and d is path length 
of diffusion. The simplest system to consider is that of slab, where drug release is 
from only one surface as shown Figure  in this case equation (4) becomes  
dMt/ dt  =    ADK C/ d                                           (5) 
 
Non permeable polymer shell 
Figure 1.4: Diagrammatic representation of slab configuration of reservoir diffusion       
                    system. 
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Where Mt = Mass of drug released after time t, dMt/dt. Steady state drug release rate 
of time„t‟; A= surface area of device.  
In equation (7) if variables of right side of equation remain constant, then left 
side of equation represents release rate of system, a true controlled release system 
with a zero-order release rate.  
A constant effective area of diffusion, diffusional path length, concentration 
difference, and diffusion coefficient are required to obtain a release rate that is 
constant. Reservoir diffusional systems have several advantages over conventional 
dosage forms. They can after zero order release of drug, kinetics of which can be 
controlled by changing the characteristics of the polymer to meet the particular drug 
and therapy conditions.  
 
Figure 1.5: Plot showing approach to steady state for reservoir device that has been      
                    stored for an extended period (the burst effect curve) and for device   
                    that has been freshly made (the time lag curve).  
Common methods used to develop reservoir type of devices include micro 
encapsulation of drug particles and press coating of tablets containing drug cores. In 
most cases particles coated by microencapsulation form a system where the drug is 
contained in the coating film as well as in the core of micro capsule. The drug release 
generally involves combination of dissolution and diffusion with dissolution being 
process that controls the release rate. If encapsulating material is selected properly 
will be the controlling process. Some materials such as membrane barrier coat alone 
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or in combination, are hardened gelatin, methyl or methylcellulose, polyhydroxy 
methacrylate hydroxypropyl methylcellulose, polydroxy methacrylate, polyvinyl 
acetate & various waxes.  
Matrix devices:  
 A matrix device, as the name implies, consists of drug dispersed 
homogenously throughout a polymer.  
 
Figure 1.6: Matrix diffusion system before release (time=0) & after partial drug     
                    Release (time=t).  
In this model drug in outside layer exposed to the bathing solution is dissolved 
first and diffused out of the matrix.  This process continues with the interface 
between  bathing solution and the solid drug moving controlled, the rate of dissolution 
of drug particles within the matrix must be faster that the diffusion rate of dissolved 
drug leaving matrix.  
Following assumptions are made in retrieving the mathematical models are:  
i. A pseudo steady state is maintained during drug release.  
ii. The diameter of drug particles is less than the average distance of drug Diffusion 
through the matrix.  
iii. The bathing solution provides sink conditions.  
iv. The diffusion coefficient of drug in the matrix remains constant.  
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 The next equation that describes the rate of release drugs dispersed in an inert 
matrix system has been derived by Higuchi.  
 
Figure 1.7: Schematic representation of the physical model used for a planer slab    
                    matrix diffusion device.  
 The change in amount of drug released per unit area dM and change in the 
thickness of the zone of the matrix that has been depleted of the drug,  
dM/dh = Co dh – Cs /2                                               (6) 
By Fick‟s first law,  
dm = (Dm Cs/h) dt.                                                      (7) 
where, Dm is diffusion coefficient in matrix if equation (6)  & (7) are equated & 
solved for D that value of h sustituted back into the integrated form of equation (7) An 
equation for M is obtained.  
M= [Cs Dm (2Co – Cs) t] ½                                         (8) 
Similarly, a drug released from porous or granular matrix is described.  
                         M= [Ds Ca (є/τ) (2Co – є Ca) t] ½                               (9) 
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Where,   e = Porosity of matrix  
               τ = tortuosity.  
              Ca = Solubility of drug in release medium  
              Ds = diffusion coefficient of drug in release medium.  
 In this system drug is leached from matrix through channels or pores.  
  M = Kt½ 
                              M = K √t                         (10) 
Where K is constantan so, that plot amount of drug released verses square root of time 
should be linear if the release of drug from the matrix is diffusion controlled.  The 
release rate of drug from such a device is not zero order, since if decreases with time 
but as previously mentioned, this may be clinically equivalent to constant drugs.  
1.5. Matrix tablets: (Chein Y.W., 2009; Harnish Patel, et al., 2011) 
Introduction of matrix tablet as sustained release (SR) has given a new 
breakthrough for novel drug delivery system (NDDS) in the field of Pharmaceutical 
technology. It excludes complex production procedures such as coating and 
pelletization during manufacturing and drug release rate from the dosage form is 
controlled mainly by the type and proportion of polymer used in the preparations. 
Hydrophilic polymer matrix is widely used for formulating SR dosage form. 
 Because of increased complication and expense involved in marketing of new 
drug entities, has focused greater attention on development of sustained release or 
controlled release drug delivery systems.  
Matrix systems are widely used for the purpose of sustained release. It is the 
release system which prolongs and controls the release of the drug that is dissolved or 
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dispersed. In fact, a matrix is defined as a well-mixed composite of one or more drugs 
with gelling agent i.e. hydrophilic polymers. By the sustained release method 
therapeutically effective concentration can be achieved in the systemic circulation 
over an extended period of time, thus achieving better compliance of patients. 
 Numerous SR oral dosage forms such as membrane controlled system, 
matrices with water soluble/insoluble polymers or waxes and osmotic systems have 
been developed, intense research has recently focused on the designation of SR 
systems for poorly water soluble drugs. 
1.5.1. Advantages of matrix tablets: 
 Easy to manufacture  
 Versatile, effective and low cost  
 Can be made to release high molecular weight compounds  
 The sustained release formulations may maintain therapeutic 
concentrations over prolonged periods.  
 The use of sustain release formulations avoids the high blood 
concentration.  
 Sustain release formulations have the potential to improve the patient 
compliance.  
 Reduce the toxicity by slowing drug absorption.  
 Increase the stability by protecting the drug from hydrolysis or other 
derivative changes in gastrointestinal tract.  
 Minimize the local and systemic side effects.  
 Improvement in treatment efficacy.  
 Minimize drug accumulation with chronic dosing.  
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 Usage of less total drug.  
 Improvement the bioavailability of some drugs.  
 Improvement of the ability to provide special effects.  
Ex: Morning relief of arthritis through bed time dosing. 
1.5.2. Disadvantages of matrix tablet: 
 The remaining matrix must be removed after the drug has been 
released.  
 High cost of preparation.  
 The release rates are affected by various factors such as, food and the 
rate transit through the gut.  
 The drug release rates vary with the square root of time. Release rate 
continuously diminishes due to an increase in diffusional resistance 
and/or a decrease in effective area at the diffusion front. However, a 
substantial sustained effect can be produced through the use of very 
slow release rates, which in many applications are indistinguishable 
from zero-order.  
1.5.3. Classification of matrix tablets:  
1.5.3.1. On the Basis of Retardant Material Used:  
Matrix tablets can be divided into 5 types.   
1. Hydrophobic Matrices (Plastic matrices): 
The concept of using hydrophobic or inert materials as matrix materials was 
first introduced in 1959. In this method of obtaining sustained release from an oral 
dosage form, drug is mixed with an inert or hydrophobic polymer and then 
compressed in to a tablet.  
Sustained release is produced due to the fact that the dissolving drug has 
diffused through a network of channels that exist between compacted polymer 
particles. Examples of materials that have been used as inert or hydrophobic matrices 
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include polyethylene, polyvinyl chloride, ethyl cellulose and acrylate polymers and 
their copolymers. The rate-controlling step in these formulations is liquid penetration 
into the matrix. The possible mechanism of release of drug in such type of tablets is 
diffusion. Such types of matrix tablets become inert in the presence of water and 
gastrointestinal fluid.  
2. Lipid Matrices:  
 These matrices prepared by the lipid waxes and related materials. Drug 
release from such matrices occurs through both pore diffusion and erosion. Release 
characteristics are therefore more sensitive to digestive fluid composition than to 
totally insoluble polymer matrix. Carnauba wax in combination with stearyl alcohol 
or stearic acid has been utilized for retardant base for many sustained release 
formulation.  
3. Hydrophilic Matrices:  
Hydrophilic polymer matrix systems are widely used in oral controlled drug 
delivery because of their flexibility to obtain a desirable drug release profile, cost 
effectiveness, and broad regulatory acceptance. The formulation of the drugs in 
gelatinous capsules or more frequently, in tablets, using hydrophilic polymers with 
high gelling capacities as base excipients is of particular interest in the field of 
controlled release. Infect a matrix is defined as well mixed composite of one or more 
drugs with a gelling agent (hydrophilic polymer). These systems are called swellable 
controlled release systems.  
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The polymers used in the preparation of hydrophilic matrices are divided into 
three broad groups,  
A. Cellulose derivatives:  
 Methylcellulose 400 and 4000Cps, Hydroxy ethylcellulose; Hydroxypropyl 
methylcellulose (HPMC) 25, 100, 4000 and 15000Cps; and Sodium carboxy methyl 
cellulose.  
B. Non cellulose natural or semi synthetic polymers:  
Agar-Agar; Carob gum; Alginates; Molasses; Polysaccharides of mannose and 
galactose, Chitosan and Modified starches.  
Polymers of acrylic acid:  
Carbopol-934, the most used variety. 
4. Biodegradable Matrices:  
These consist of the polymers which comprised of monomers linked to one 
another through functional groups and have unstable linkage in the backbone. They 
are biologically degraded or eroded by enzymes generated by surrounding living cells 
or by non-enzymatic process in to oligomers and monomers that can be metabolized 
or excreted. Examples are natural polymers such as proteins and polysaccharides; 
modified natural polymers; synthetic polymers such as aliphatic poly (esters) and poly 
anhydrides. 
5. Mineral Matrices:  
These consist of polymers which are obtained from various species of 
seaweeds. Example is Alginic acid which is a hydrophilic carbohydrate obtained from 
species of brown seaweeds (Phaephyceae) by the use of dilute alkali.  
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1.5.3.2. On the Basis of Porosity of Matrix:  
Matrix system can also be classified according to their porosity and 
consequently, Macro porous; Micro porous and Non-porous systems can be 
identified:  
1. Macro porous Systems:  
In such systems the diffusion of drug occurs through pores of matrix, which 
are of size range 0.1 to 1 μm. This pore size is larger than diffusant molecule size.  
2. Micro porous System:  
Diffusion in this type of system occurs essentially through pores. For micro 
porous systems, pore size ranges between 50 – 200 A°, which is slightly larger than 
diffusant molecules size. 
 3. Non-porous System:  
Non-porous systems have no pores and the molecules diffuse through the 
network meshes. In this case, only the polymeric phase exists and no pore phase is 
present.  
1.5.4. Polymers used in matrix tablet:  
Hydrogels:  
Polyhydroxy ethyl methacrylate (PHEMA), Cross-linked polyvinyl alcohol 
(PVA), Cross-linked polyvinyl pyrrolidone (PVP), Polyethylene oxide (PEO), Poly 
acrylamide (PA). 
Soluble polymers:  
Polyethyleneglycol (PEG), polyvinyl alcohol (PVA), Polyvinyl pyrrolidone 
(PVP), Hydroxypropyl methyl cellulose (HPMC).  
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Biodegradable polymers:  
Polylactic acid (PLA), Polyglycolic acid (PGA), Poly caprolactone (PCL), 
Poly anhydrides, Poly orthoesters.  
Non-biodegradable polymers:  
Polyethylene vinyl acetate (PVA), Poly dimethyl siloxane (PDS), Polyether 
urethane (PEU), Polyvinyl chloride (PVC), Cellulose acetate (CA), Ethyl cellulose 
(EC).  
Mucoadhesive polymers:  
Poly carbophil, Sodium carboxy methylcellulose, Polyacrylic acid, 
Tragacanth, Methyl cellulose, Pectin.  
Natural gums: Xanthan gum, Guar gum, Karaya gum, Locust bean gum. 
1.5.5. Mechanism of drug release from matrix tablet: 
Drug in the outside layer exposed to the bathing solution is dissolved first and 
then diffuses out of the matrix. This process continues with the interface between the 
bathing solution and the solid drug moving toward the interior. It follows that for this 
system to be diffusion controlled, the rate of dissolution of drug particles within the 
matrix must be much faster than the diffusion rate of dissolved drug leaving the 
matrix. Derivation of the mathematical model to describe this system involves the 
following assumptions:  
a) A pseudo-steady state is maintained during drug release,  
b) The diameter of the drug particles is less than the average distance of drug 
diffusion through the matrix,  
c) The bathing solution provides sink conditions at all times.  
 
Lamivudine Sustained Release Matrix Tablets                  INTRODUCTION 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur.  27 
 
1.6. Methods used in tablet manufacturing:   (Lieberman H.A. and Lachman L., 
1999; Ansel H.C., 2009; http://www.pharmainfo.net) 
Granulation:       
 Granulation may be defined as a size enlargement process which converts 
small particles into physically stronger & larger agglomerates. 
The reason for granulation: 
  Become the pharmaceutical ingredient are free flowing 
  Increase the denseness of  ingredient 
  We can formulate uniform granular size that does not existing apart  
  Produce better  compression  characteristic  of  drug 
  Controlling  the  rate of  drug release from the dosage form 
  Reduce  dust in granulation technique 
  The  appearance  of  tablet can be achieved 
Methods: 
  1. Direct compression  
  2. Wet granulation 
  3. Dry granulation     
1.6.1. Direct compression: 
                In early days, most of the tablets require granulation of the powdered Active 
Pharmaceutical Ingredient (API) and Excipients. At the availability of new excipients 
or modified form of old excipients and the invention of new tablet machinery or 
modification of old tablet machinery provides an ease in manufacturing of tablets by 
simple procedure of direct compression. 
            Amongst the techniques used to prepare tablets, direct compression is the most 
advanced technology. It involves only blending and compression. Thus offering 
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advantage particularly in terms of speedy production. Because it requires fewer unit 
operations, less machinery, reduced number of personnel and considerably less 
processing time along with increased product stability. 
1.6.1.1. Definition:  
 The term “direct compression” is defined as the process by which tablets are 
compressed directly from powder mixture of API and suitable excipients. No 
pretreatment of the powder blend by wet or dry granulation procedure is required. 
1.6.1.2. The events that motivates the industry people to use direct compression 
technique:  
I. Commercial availability of the directly compressible excipients possessing         
both good compressibility and good flowability. For example,  
Spray dried lactose, Anhydrous lactose, Starch-1500, microcrystalline cellulose, Di-
Pac
Ò
, sorbitol. 
II. Major advances in tablet compression machinery: 
i)  Improved positive die feeding, 
ii) Precompression of powder blend. 
1.6.1.3 Merits: 
i) Direct compression is more efficient and economical process as compared to other 
processes, because it involves only dry blending and compaction of API and 
necessary excipients. 
ii) The most important advantage of direct compression is economical process. 
Reduced processing time, reduced labor costs, fewer manufacturing steps, and less 
number of equipments are required, less process validation, reduced consumption of 
power.  
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iii) Elimination of heat and moisture, thus increasing not only the stability but also the 
suitability of the process for thermolabile and moisture sensitive API‟s. 
iv) Particle size uniformity. 
v) Prime particle dissolution. 
 In case of directly compressed tablets after disintegration, each primary drug 
particle is liberated. While in the case of tablets prepared by compression of granules, 
small drug particles with a larger surface area adhere together into larger 
agglomerates; thus decreasing the surface area available for dissolution. 
vi) The chances of batch-to-batch variation are negligible, because the unit operations 
required for manufacturing processes is fewer. 
vii) Chemical stability problems for API and excipient would be avoided. 
viii) Provides stability against the effect of aging which affects the dissolution rates. 
1.6.1.4. Merits over wet granulation process: 
 The variables faced in the processing of the granules can lead to significant 
tableting problems. Properties of granules formed can be affected by viscosity of 
granulating solution, the rate of addition of granulating solution, type of mixer used 
and duration of mixing, method and rate of dry and wet blending. The above variables 
can change the density and the particle size of the resulting granules and may have a 
major influence on fill weight and compaction qualities. Drying can lead to 
unblending as soluble API migrates to the surface of the drying granules. 
1.6.1.5. Demerits: 
Excipients Related:  
i) Problems in the uniform distribution of low dose drugs. 
ii) High dose drugs having high bulk volume, poor compressibility and poor 
flowability are not suitable for direct compression. 
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iii) The choice of excipients for direct compression is extremely critical. 
Direct compression diluents and binders must possess both good 
compressibility and good flow ability. 
iv)  Many active ingredients are not compressible either in crystalline or 
amorphous forms. 
v) Direct compression blends may lead to unblending because of difference 
in particle size or density of drug and excipients. Similarly the lack of 
moisture may give rise to static charges, which may lead to unblending. 
vi) Non-uniform distribution of colour, especially in tablets of deep colours. 
Process Related: 
i) Capping, lamination, splitting, or layering of tablets is sometimes related to air 
entrapment during direct compression. When air is trapped, the resulting tablets 
expand when the pressure of tablet is released, resulting in splits or layers in the 
tablet. 
ii) In some cases require greater sophistication in blending and compression 
equipments. 
iii) Direct compression equipments are expensive. 
1.6.1.6. Manufacturing steps for direct compression: 
 Direct compression involves comparatively few steps: 
  Milling of drug and excipients. 
  Mixing of drug and excipients. 
  Tablet compression. 
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Figure 1.8: Manufacturing Steps for Direct Compression. 
1.6.1.7. Direct compression Excipients: 
 Direct compression excipients mainly include diluents, binders and 
disintegrants. Generally these are common materials that have been modified during 
the chemical manufacturing process, in such a way to improve compressibility and 
flowability of the material. 
 The physicochemical properties of the ingredients such as particle size, 
flowability and moisture are critical in direct compression tableting. The success of 
direct compression formulation is highly dependent on functional behavior of 
excipients. 
1.6.1.7.1. An ideal direct compression excipient should possess the following 
attributes:  
 i)  It should have good compressibility. 
ii) It should possess good hardness after compression, that is material should not 
possess any deformational properties; otherwise this may lead to capping and 
lamination of tablets. 
iii) It should have good flowability. 
iv) It should be physiologically inert. 
v) It should be compatible with wide range of API. 
vi) It should be stable to various environmental conditions (air, moisture, heat, etc.). 
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vii) It should not show any physical or chemical change in its properties on aging. 
viii) It should have high dilution potential i.e. able to incorporate high amount of API. 
 ix) It should be colourless, odorless and tasteless. 
x) It should accept colourants uniformity. 
xi) It should possess suitable organoleptic properties according to formulation type, 
that is in case of chewable tablet diluent should have suitable taste and flavor. For 
example, mannitol produces cooling sensation in mouth and also sweet test. 
xii) It should not interfere with bioavailability and biological activity of active 
ingredients. 
xiii) It should be easily available and economical in cost. 
Granulation method can be broadly classified into two types:  
 Wet granulation and  
 Dry granulation. 
1.6.2. Wet granulation: 
The most widely used process of agglomeration in pharmaceutical industry is 
wet granulation. Wet granulation process simply involves wet massing of the powder 
blend with a granulating liquid, wet sizing and drying. 
1.6.2.1. Important steps involved in the wet granulation: 
i)   Mixing of the drug(s) and excipients 
ii)  Preparation of binder solution 
iii) Mixing of binder solution with powder mixture to form wet mass. 
iv) Coarse screening of wet mass using a suitable sieve (6-12 # screens). 
v)  Drying of moist granules. 
vi) Screening of dry granules through a suitable sieve (14-20 # screen). 
vii)  Mixing of screened granules with disintegrant, glidant, and lubricant. 
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1.6.2.2. Limitations of wet granulation: 
i)  The greatest disadvantage of wet granulation is its cost. It is an expensive process 
because of labor, time, equipment, energy and space requirements. 
ii) Loss of material during various stages of processing  
iii) Stability may be major concern for moisture sensitive or thermo labile drugs  
iv) Multiple processing steps add complexity and make validation and control 
difficult. 
v) An inherent limitation of wet granulation is that any incompatibility between 
formulation components is aggravated. 
1.6.3. Dry granulation: 
In dry granulation process the powder mixture is compressed without the use 
of heat and solvent. It is the least desirable of all methods of granulation. The two 
basic procedures are to form a compact of material by compression and then to mill 
the compact to obtain a granules. Two methods are used for dry granulation. The 
more widely used method is slugging, where the powder is pre-compressed and the 
resulting tablet or slug are milled to yield the granules.  
The other method is to pre-compress the powder with pressure rolls using a 
machine such as Chilosonator. 
1.6.3.1. Advantages: 
The main advantages of dry granulation or slugging are that it uses less 
equipments and space. It eliminates the need for binder solution, heavy mixing 
equipment and the costly and time consuming drying step required for wet 
granulation. Slugging can be used for advantages in the following situations: 
i) For moisture sensitive material 
ii) For heat sensitive material 
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iii) For improved disintegration since powder particles are not bonded together by a 
binder 
1.6.3.2. Disadvantages: 
i) It requires a specialized heavy duty tablet press to form slug 
ii) It does not permit uniform colour distribution   
iii) Achieved with wet granulation where the dye can be incorporated into binder 
liquid. 
iv) The process tends to create more dust than wet granulation, increasing the 
potential contamination. 
1.7. AIDS and HIV review:                          (http://www.emedicinehealth.com; 
http://www.biog1105-1106.org) 
HIV (Human Immunodeficiency Virus) infection has now spread to every country 
in the world. Approximately 40 million people are currently living with HIV 
infection, and an estimated 25 million have died from this disease. The scourge of 
HIV has been particularly devastating in sub-Saharan Africa, but infection rates in 
other countries remain high. In the United States, approximately 1 million people are 
currently infected. Here are a few key points about the disease: 
 Globally, 85% of HIV transmission is heterosexual. 
 In the United States, approximately one-third of new diagnoses appear to be 
related to heterosexual transmission. Male-to-male sexual contact still 
accounts for approximately half of new diagnoses in the U.S. Intravenous drug 
use contributes to the remaining cases. Because the diagnosis may occur years 
after infection, it is likely that a higher proportion of recent infections are due 
to heterosexual transmission. 
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 Infections in women are increasing. Worldwide, 42% of people with HIV are 
women. In the United States, approximately 25% of new diagnoses are in 
women, and the proportion is rising. 
 There is good news on one front. New HIV infections in U.S. children have 
fallen dramatically. This is largely a result of testing and treating infected 
mothers, as well as establishing uniform testing guidelines for blood products.  
 In order to understand HIV and AIDS, it is important to understand the 
meanings behind these terms: 
 HIV stands for the human immunodeficiency virus. It is one of a group of 
viruses known as retroviruses. After getting into the body, the virus kills or 
damages cells of the body's immune system. The body tries to keep up by 
making new cells or trying to contain the virus, but eventually the HIV wins 
out and progressively destroys the body's ability to fight infections and certain 
cancers. 
 AIDS stands for the acquired immunodeficiency syndrome. It is caused by 
HIV and occurs when the virus has destroyed so much of the body's defenses 
that immune-cell counts fall to critical levels or certain life-threatening 
infections or cancers develop.  
1.7.1. HIV/AIDS Transmission: 
HIV is transmitted when the virus enters the body, usually by injecting infected 
cells or semen. There are several possible ways in which the virus can enter. 
 Most commonly, HIV infection is spread by having sex with an infected 
partner. The virus can enter the body through the lining of the vagina, vulva, 
penis, rectum, or mouth during sex. 
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 HIV frequently spreads among injection-drug users who share needles or 
syringes that are contaminated with blood from an infected person. 
 Women can transmit HIV to their babies during pregnancy or birth, when 
infected maternal cells enter the baby's circulation. 
 HIV can be spread in health-care settings through accidental needle sticks or 
contact with contaminated fluids. 
 Very rarely, HIV spreads through transfusion of contaminated blood or blood 
components. Blood products are now tested to minimize this risk. If tissues or 
organs from an infected person are transplanted, the recipient may acquire 
HIV. Donors are now tested for HIV to minimize this risk. 
 People who already have a sexually transmitted disease, such as syphilis, 
genital herpes, chlamydial infection, gonorrhea, or bacterial vaginosis, are 
more likely to acquire HIV infection during sex with an infected partner.  
The virus does not spread through casual contact such as preparing food, sharing 
towels and bedding, or via swimming pools, telephones, or toilet seats. The virus is 
also unlikely to be spread by contact with saliva, unless it is contaminated with blood.                                                                                                                             
1.7.2. Structure of HIV:  
The two copies of the viral RNA are protected by a protein coat and enclosed 
in a capsule. Also contained in the capsule are reverse transcriptase enzymes (which 
convert the single-stranded RNAs into double-stranded DNA copies), integrase 
(which inserts the DNA version into the host genome), and protease (which cuts the 
long chain of polypeptides produced by viral RNA into individual enzyme 
components as new virus particles are budding off a cell membrane). The capsule is 
itself enclosed in a bilayer membrane obtained from the previous host cell; in the 
membrane are mounted P17 (the remains of a protein involved in budding off) and 
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GP120 (the glycoprotein that binds the helper T-cell receptor and so enables the virus 
to gain entry into its host). 
 
Figure 1.9: Structure of HIV. 
1.7.3. HIV/AIDS Symptoms and Signs: 
Many people with HIV do not know they are infected. 
 Many people do not develop symptoms after they first get infected with HIV. 
Others have a flu-like illness within several days to weeks after exposure to 
the virus. They complain of fever, headache, tiredness, and enlarged lymph 
nodes in the neck. These symptoms usually disappear on their own within a 
few weeks. After that, the person feels normal and has no symptoms. This 
asymptomatic phase often lasts for years. 
 The progression of disease varies widely among individuals. This state may 
last from a few months to more than 10 years. 
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o During this period, the virus continues to multiply actively and infects 
and kills the cells of the immune system. 
o The virus destroys the cells that are the primary infection fighters, a 
type of white blood cell called CD4 cells. 
o Even though the person has no symptoms, he or she is contagious and 
can pass HIV to others through the routes listed above. 
 AIDS is the later stage of HIV infection, when the body begins losing its 
ability to fight infections. Once the CD4 cell count falls low enough, an infected 
person is said to have AIDS. Sometimes, the diagnosis of AIDS is made because the 
person has unusual infections or cancers that show the weak immune system. 
 The infections that happen with AIDS are called opportunistic infections 
because they take advantage of the opportunity to infect a weakened host. The 
infections include (but are not limited to) 
o Pneumonia caused by Pneumocystis, which causes wheezing; 
o Brain infection with toxoplasmosis which can cause trouble thinking or 
symptoms that mimic a stroke; 
o Widespread infection with a bacteria called MAC (mycobacterium 
avium complex) which can cause fever and weight loss; 
o Yeast infection of the swallowing tube (esophagus) which causes pain 
with swallowing; 
o Widespread diseases with certain fungi like histoplasmosis, which can 
cause fever, cough, anemia, and other problems. 
 A weakened immune system can also lead to other unusual conditions: 
o Lymphoma in (a form of cancer of the lymphoid tissue) the brain, 
which can cause fever and trouble thinking; 
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o A cancer of the soft tissues called Kaposi's sarcoma, which causes 
brown, reddish, or purple spots that develop on the skin or in the 
mouth.  
1.7.4. HIV/AIDS Diagnosis: 
 HIV infection is commonly diagnosed by blood tests. There are three main 
types of tests that are commonly used: (1) antibody tests, (2) RNA tests, and (3) a 
combination test that detects both antibodies and a piece of the virus called the p24 
protein. In addition, a blood test known as a Western blot is used to confirm the 
diagnosis. 
 Testing for HIV is usually a two-step process. First, an inexpensive screening 
test is done. If that test is positive, a second test (Western blot) is done to confirm the 
result. Antibody tests are the most common initial screening test used. There are 
different types of antibody screening tests available: 
 Most commonly, blood is drawn for an enzyme immunoassay (EIA). The test 
is usually run in a local laboratory, so results can take one to three days to 
come back. 
 Other tests can detect antibodies in body fluids other than blood such as saliva, 
urine, and vaginal secretions. Some of these are designed to be rapid tests that 
produce results in approximately 20 minutes. These tests have accuracy rates 
similar to traditional blood tests. 
 HIV home-testing kits are available at many local drug stores. Blood is 
obtained by a finger prick and blotted on a filter strip. Other test kits use saliva 
or urine. The filter strip is mailed in a protective envelope to a laboratory to be 
tested. Results are returned by mail in one to two weeks. 
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 All positive antibody screening tests must be confirmed with a follow-up 
blood test called the Western blot to make a positive diagnosis. If the antibody 
test and the Western blot are both positive, the likelihood of a person being 
HIV infected is >99%. Sometimes, the Western blot is "indeterminate," 
meaning that it is neither positive nor negative. In these cases, the tests are 
usually repeated at a later date. In addition, an RNA test for the virus might be 
done.   
Other tests, such as those that look for virus RNA and the combination tests are not 
commonly used for screening. 
1.7.5. HIV/AIDS Treatment: 
Medications:  
The following are the different classes of medications used in treatment. 
 Reverse transcriptase inhibitors: These drugs inhibit the ability of the virus 
to make copies of itself. The following are examples: 
o Nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs). 
These include medications such as zidovudine (AZT/Retrovir), 
didanosine (ddI/Videx), zalcitabine (ddC/Hivid), stavudine (d4T/Zerit), 
lamivudine (3TC/Epivir), abacavir (ABC/Ziagen), emtricitabine 
(FTC/Emtriva), and tenofovir (Viread). 
o Non-nucleoside reverse transcriptase inhibitors (NNRTIS) are 
commonly used in combination with NRTIs to help keep the virus 
from multiplying. Examples of NNRTIs are efavirenz (Sustiva), 
nevirapine (Viramune), and delavirdine (Rescriptor). Etravirine 
(Intelence), a newer member of this class of drugs, was approved by 
the U.S. FDA in 2008. 
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 Protease inhibitors (PIs):  
 These medications interrupt virus replication at a later step in its life 
cycle, preventing cells from producing new viruses. These include ritonavir 
(Norvir), a lopinavir and ritonavir combination (Kaletra), saquinavir 
(Invirase), indinavir sulphate (Crixivan), amprenavir (Agenerase), 
fosamprenavir (Lexiva), darunavir (Prezista), atazanavir (Reyataz), tipranavir 
(Aptivus), and nelfinavir (Viracept). Using PIs with NRTIs reduces the 
chances that the virus will become resistant to medications. 
 Fusion and entry inhibitors are newer agents that keep HIV from entering 
human cells. Enfuvirtide (Fuzeon/T20) was the first drug in this group. It is 
given in injectable form like insulin. Another drug called maraviroc 
(Selzentry) binds to a protein on the surface of the human cell and can be 
given by mouth. Both drugs are used in combination with other anti-HIV 
drugs. 
 Integrase inhibitors stop HIV genes from becoming incorporated into the 
human cell's DNA. This is a newer class of drugs recently approved to help 
treat those who have developed resistance to the other medications. 
Raltegravir (Isentress) was the first drug in this class approved by the FDA in 
2007.  
 Anti-retroviral drugs stop viral replication and delay the development of 
AIDS. However, they also have side effects that can be severe. They include 
decreased levels of red or white blood cells, inflammation of the pancreas, liver 
toxicity, rash, gastrointestinal problems, elevated cholesterol level, diabetes, abnormal 
body-fat distribution, and painful nerve damage. 
Lamivudine Sustained Release Matrix Tablets                  INTRODUCTION 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur.  42 
 
 Pregnant women who are HIV-positive should seek care immediately because 
HAART therapy reduces the risk of transmitting the virus to the fetus.       
There are certain drugs, however, that are harmful to the baby.          
Therefore, seeing a physician to discuss anti-HIV medications is crucial. 
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2. NEED AND OBJECTIVES 
 
  
Need of this work are: 
 Lamivudine is approved for clinical use and used widely in treatment of 
Hepatitis B and AIDS either alone or in combination with another antiviral 
drugs because of its water solubility and shorter half -life (6 hours) drug 
requires frequent dosing by oral route, of various recent techniques for 
controlling drug release, matrix system offer various advantages of ease of 
formulation better control on release profile of drug and better patient 
compliance. 
 The pronounced fluctuation resulting from the conventional drug 
administration are likely to yield period of therapeutic effects when the 
concentration falls below the minimum therapeutic drug concentration and can 
be controlled within the narrow therapeutic range by use of sustained release 
system. Which will minimize the severity of side effects.  
 Hydrophilic and hydrophobic polymer matrix system are widely used for 
designing oral sustained release drug delivery dosage form because of their 
flexibility to provide a desirable drug release profile, cost effectiveness and 
broad regulatory acceptance.  
 Large scale production needs more simplicity in the formulation with 
economic and cheapest dosage form. The matrix tablets formulation by direct 
compression method is most acceptable in large scale production.
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Objectives of the work are: 
 To  evaluate the physical characters of prepared sustained release tablets  
 To  elucidate the effect of polymer composition, on the release kinetics and  
 To determine the chemical compatibility of formulation containing various 
ratios of polymer and drug.  
Lamivudine (β-L- 2‟, 3‟-dideoxy-3‟-thiacytidine), one of the dideoxy cytidine 
analogue NRTIs, is the first nucleoside analogue approved to treat chronic HBV 
infection and AIDS.  
Conventional oral formulations of lamivudine are administered multiple times a 
day (150 mg twice daily) because of its moderate half-life (t1/2 = 6 hours). 
Treatment of AIDS using conventional formulations of lamivudine is found to 
have many drawbacks, such as adverse side effects resulting from accumulation of 
drug in multi-dose therapy, poor patient compliance, and high cost. Sustained release 
once-daily formulations of lamivudine can overcome some of these problems. 
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3. PLAN OF WORK 
 
The present work was carried out to design and evaluate sustained-release 
tablets of lamivudine, an anti retroviral drug. The sustained-release matrix tablets 
were prepared by direct compression method using HPMC K4M, ethyl cellulose, 
methyl cellulose, PVP K30, magnesium stearate and talc keeping in view the 
objectives described above the following plan of work was adopted. 
THE SCHEME OF THE ENTIRE WORK IS LISTED AS FOLLOWS: 
 Literature review 
 Selection of drug and excipients 
 Procurement of drug and excipients 
 Physicochemical studies (organoleptic properties, melting point and solubility)  
  Standardization of the method and construction of calibration curve for the 
estimation of lamivudine, quantification of drug. 
  Compatibility studies of drug and polymer by FTIR spectral and DSC studies 
 Formulation of lamivudine sustained release matrix tablets by using polymers 
like HPMC K4M, ethyl cellulose and methyl cellulose by direct compression 
method. 
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   Evaluation of blend characteristics of  prepared granules (pre-compression 
parameters) 
i. Angle of repose 
ii. Determination of bulk density 
iii. Determination of tapped density 
iv. Compressibility index 
v. Hausner ratio 
   Evaluation of physical parameters of lamivudine sustained-release tablets (post-
compression parameters) 
                      i.    Thickness and diameter 
 ii.    Hardness 
iii. Friability 
iv. Weight variation 
v. Drug content  
 Evaluation of in vitro release characteristics of all formulations by using USP 
dissolution apparatus type I (Basket). 
 To study the mechanism of drug release by applying kinetic parameters. 
 To perform stability studies as per ICH guidelines.
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4. LITERATURE REVIEW 
 
Ahmed A., et al. (2008) estimated the influence of EC with different viscosity 
grades on in vitro drug release from EC matrix tablets containing Indomethacin. Four 
viscosity grades were studied (7, 10, 50 and 100 cps). The drug release from the tablet 
is determined by dissolution testing as described in the USP. Based upon the pore 
characteristic studies which was determined by using helium pycnometry and mercury 
porosimetry the release rate constant has been found for different viscosity grades. 
From the result it is indicated the release rate is increased with an increase in viscosity 
grade. 
Amelia Avachat, et al. (2007) was developed and characterized an oral 
controlled release drug delivery system for concomitant administration of diclofenac 
sodium (DS) and chondroitin sulfate (CS). A hydrophilic matrix-based tablet using 
different concentrations of hydroxypropyl methylcellulose (HPMC) was developed 
using wet granulation technique to contain 100 mg of DS and 400 mg of CS. 
Formulations prepared were evaluated for the release of DS and CS over a period of 9 
hours in pH 6.8 phosphate buffer using United States Pharmacopoeia (USP) type II 
dissolution apparatus. Along with usual physical properties, the dynamics of water 
uptake and erosion degree of tablets were also investigated. The in vitro drug release 
study revealed that HPMC K100 CR at a concentration of 40% of the dosage form 
weight was able to control the simultaneous release of both DS and CS for 9 hours. 
The release of DS matched with the marketed CR tablet of DS with similarity factor 
(f2) above 50. 
Deepak S., et al. (2010) had developed sustained release formulation of 
quetiapine fumarate using HPMC and PVP K30. The study involves fixing the drug 
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and polymer ratio for control the drug release up to the desired time. The effect of 
polymer concentration and polymer blend concentration were also studied. 
Dissolution studies were performed in 0.1N HCl for 2 hrs and in phosphate buffer up 
to 12 hours. From the release it was observed that the polymer blend of HPMC/PVP 
K30 were successfully sustained the release of drug up to 12 hrs.  
Gohel M.C., et al. (2007) was developed modified release of isoniazid using 
hydroxypropyl methylcellulose as a rate controlling agent. The low viscosity grade 
hydroxypropyl methylcellulose, medium viscosity grade hydroxypropyl 
methylcellulose and high viscosity grade Hydroxypropyl methylcellulose were used 
to prepare the matrix tablets. The tablets, prepared by direct compression, were 
subjected to physical characterization and in-vitro drug release studies. The release 
rate was strongly influenced by the type of polymer and concentration of polymer. 
Harris Shoaib M., et al. (2006) had formulated a once daily sustained release 
matrix tablet of ibuprofen using HPMC as release controlling factor and to evaluate 
drug release parameters as per various release kinetic models. The tablets were 
directly compressed using Avicel pH 101 and magnesium stearate. Different 
dissolution models were applied to drug release data in order to evaluate release 
mechanism. The drug release data fit well to the Higuchi expression. 
Indranil Kumar Yadav, et al. (2010) was developed the oral sustained 
release matrix tablets of aceclofenac using hydrophilic and hydrophobic polymers. 
Aceclofenac is a non steroidal anti-inflammatory agent used in symptomatic treatment 
of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis and its biological 
half life is 4hrs. Controlled release formulations of aceclofenac (200 mg) were 
prepared by direct compression method. The tablets were subjected to 
physicochemical, in-vitro drug release and stability studies. The drug release from 
Lamivudine Sustained Release Matrix Tablets            LITERATURE REVIEW 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur.  49 
 
optimized formulations F1, F4 and F7 was extended for a period of 12 hrs. The 
optimized formulations were subjected to stability studies for three months at 45°C 
temperature with RH 75±5%, and showed stability with respect to physicochemical 
parameters and release pattern. Results of the present study indicated the suitability of 
hydrophilic and hydrophobic polymers in the preparation of matrix based sustained 
release formulation of aceclofenac. 
Kalyani C., et al. (2009) had designed oral sustained matrix tablets of 
zidovudine using HPMC K4M, guar gum and ethyl cellulose as the retardant 
polymers. Factors like polymer proportion, polymer type and effect of filler type on 
the in vitro release of the drug. The formulations were prepared by wet granulation 
technique. The granules were evaluated and all formulations showed compliance with 
pharmacopoeial standards. Formulation F2 and F8 sustained the release for 12 hrs. 
Formulation F5 was found to be best which contains 15% HPMC using MCC as 
diluent release 10 hours only. 
Kumar pal T., et al. (2007) was designed an oral sustained release matrix 
tablet of metformin HCl and to optimize the drug release profile using response 
surface methodology. Tablets were prepared by non-aqueous wet granulation method 
using HPMC K15M as matrix forming polymer. 
Madhusmruti K., et al. (2010) was developed sustain release matrix 
formulation of Propanolol hydrochloride and investigate the effects of both 
hydrophilic and hydrophobic polymer on in-vitro drug release. Matrix tablets were 
prepared by direct compression method using different concentrations of 
Hydroxypropyl methyl cellulose (HPMC) and Ethyl Cellulose (EC). Prepared 
formulations were subjected to various studies like hardness, friability, thickness, % 
drug content, weight variation, dynamic of water uptake and erosion etc. Tablets were 
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subjected to in-vitro drug release in 0.1N HCl (pH 1.2) for first 2 hours followed by 
phosphate buffer (pH 6.8) remaining time. 
Patil U.K., et al. (2008) prepared and evaluated sustained release matrix tablet 
using natural polymers like pectin, guar gum and xanthan gum. Furosemide is used as 
the model drug and the formulations were compressed by a direct compression. The 
tablets were evaluated for physical characteristic and all the formulations were found 
to be in acceptable limits. Among the polymers guar gum was found to exhibit greater 
swelling index than pectin and xanthan gum.  
Paul J. Sheskey, et al. (1994) was studied the effect of roller compaction in 
the dry granulation of a controlled-release (CR) matrix formulation containing 
methylcellulose or hydroxypropyl methylcellulose (HPMC), niacinamide, and 
magnesium stearate. The authors investigated the use of roller compaction to enhance 
material flow in CR tablet formulations and evaluated the effect of roller compaction 
variables, such as roller pressure and product recycle, on tablet physical 
characteristics and drug-release profiles. 
Prabu Moses, et al. (2010) had formulated Ciprofloxacin controlled release 
matrix tablets using HPMC K100M, Guar gum, Carboxy methylcellulose, starch, 
polyvinyl pyrrolidone k30, magnesium stearate, isopropyl alcohol. Formulated tablets 
were taken to evaluation studies such as hardness, weight variation, friability, drug 
content and thickness. 
Raghuram Reddy K., et al. (2003) had formulated once daily sustained 
release matrix tablets of nicorandil, a novel potassium channel openers used in the 
treatment of cardiovascular disease. The tablets are prepared by wet granulation 
technique using ethanolic solutions of ethylcellulose (EC), Eudragit RL-100, Eudragit 
RS-100, and polyvinyl pyrrolidone as granulating agents with hydrophilic matrix 
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materials such as HPMC, sodium carboxylic cellulose and sodium alginate.  The 
granules were studied for physiochemical characteristics and for evaluation 
parameters. Granules showed good flow property and tablet formulations are all 
within official limits. From the dissolution studies the formulation F1 could extend 
the release for 24 hrs and thus it exhibited the most successful formulation of the 
study. 
Raju Manda, et al. (2010) was developed a sustained release matrix tablet of 
aceclofenac using different natural polymers (Guar gum, Xanthan gum, Chitosan) in 
various proportions as release controlling factor by direct compression method. The in 
vitro dissolution study was carried out for 11 hours using United States 
Pharmacopoeia (USP) 1 Basket-type dissolution apparatus in 0.1N hydrochloric acid 
for first 2 hours and phosphate buffer pH 7.4 for 9 hours. The in vitro release study 
shows that only F9 formulation was releases the drug in a sustained manner for 11 
hours. This study explored the optimum concentration and effect of polymer(s) on 
acelofenac release pattern from the tablet matrix for 11 hour period. 
Saleh M. Saidan, et al. (2005) developed guar gum matrix tablets for oral 
controlled release of water-soluble Diltiazem hydrochloride prepared by using 
microcrystalline cellulose, starch, magnesium stearate and talc. In vitro drug release 
studies were performed using USP dissolution rate apparatus. 
Sandip B. Tiwari, et al. (2003) had formulated Tramadol hydrochloride using 
hydrophilic and hydrophobic matrix system for controlled release. The effect of 
concentration of hydrophilic and hydrophobic polymers on the release rate of 
Tramadol was studied. Hydrophilic matrix tablets prepared by wet granulation 
technique, while hydrophobic matrix tablets prepared by melt granulation technique. 
In vitro dissolution studies were performed. 
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Saravanabhavan Shanmugam, et al. (2010) was developed sustained release 
matrix tablets of aceclofenac. The tablets were prepared with different ratios of 
hydroxypropyl methylcellulose K100M and ethylcellulose by wet granulation 
technique. The solubility study of the aceclofenac was conducted to select a suitable 
dissolution medium for in vitro drug release studies. In vitro dissolution study was 
carried out for all the formulation and the results compared with marketed sustained 
release tablets. The drug release from matrix tablets was found to decrease with 
increase in polymer ratio of hydroxypropyl methylcellulose as well as ethylcellulose. 
Formulation F3 exhibited almost similar drug release profile in different dissolution 
media as that of marketed tablets.  
Seema Pushkar, et al. (2009) was developed the extended release tableted 
matrix devices for once daily dosing of diclofenac sodium, and their evaluation for 
performance and compliance with official pharmacopoeial and allied pharmaceutical 
requirements. The matrix tablets were prepared by drug incorporated polymer matrix, 
formulated using different combinations and ratios of hydroxypropyl methylcellulose 
(HPMC), sodium carboxy methylcellulose (Sodium CMC), and sodium alginate 
(NaAlg). Several preformulation trials were conducted to study the effect and 
optimization of various formulation and process parameters. The drug loaded 
polymeric matrices so prepared were compressed to tablets and studied for drug the 
release behaviour and comparative kinetic characterization along with six popular 
marketed brands of Diclofenac SR tablets. The formulated granules and tablets 
compressed complied with compendial and mechanistic requirements. The in vitro 
results shown a better release profile of formulated delivery system when compared to 
marketed brands extended up to 24 hours. The various formulations have shown an 
extended release up to 11 – 23 hours in different release environments. 
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Sundaramoorthy K., et al. (2011) had formulated monolithic matrix tablets 
of metformin hydrochloride as extended release tablets by employing ethyl cellulose 
polymer and the extended release characterization of the formulated tablets was 
investigated. Extended release matrix tablets containing 500 mg metformin 
hydrochloride were developed by changing concentration of drug: polymer (EC) in 
the ratio of 5:1, 5:2, 5:3 and 5:4 by direct compression. Formulations were optimized 
based on the acceptable tablet properties in-vitro and in-vivo drug release. The result 
of in-vitro and in-vivo drug release studies indicated that formulation (drug: polymer 
=5:3), was the most successful of the study and exhibited constant and extended 
release of metformin hydrochloride 99-100.5% release at the end of 10 hours 
compared with reference standard. A decrease in release of the drug was observed on 
increasing polymer ratio at certain level. The t25%, t50% and t90% drug release values 
were calculated from selected formulation F3 on every specified period of stability 
studies and comparison of both room and accelerated condition by statistical t-test, 
there was no difference between storage temperature. The formulation F3 was showed 
similar in-vitro and in-vivo drug release when compared to market sustained release 
tablet (F5M). 
 
 Literature review indicating work carried out on selected drug lamivudine is 
given below: 
Althaf A.S., et al. (2010) was designed oral sustained release matrix tablets of 
lamivudine using hydroxypropyl methylcellulose and ethylcellulose as retardant 
polymers and to study the effect of various mixtures of drug and polymers on the 
release profile of the formulation. The in vitro studies revealed that the formulation F7 
can be taken as an ideal or optimized formulation of sustained release tablets for 16 
hours release as it fulfills all the requirements for sustained release tablet. 
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Potu Apparao, et al. (2011) had formulated and evaluated gum based 
sustained release matrix tablets of Lamivudine using different natural polymers such 
as Guar gum, Xanthan gum, Rosin gum, Pectin, and Sodium alginate taken at 30%, 
40% and 50% of the total weight of the tablet. Lamivudine is a potent hydrophilic anti 
viral agent indicated for treatment of AIDS (Acquired Immunodeficiency Syndrome). 
All the formulations were able to retard the release of the drug beyond 18 hours 
except pectin and sodium alginate were unable to sustain the drug release from the 
matrix tablets. F5 (40% Xanthan Gum) formulation was selected as optimized 
formulation. 
Ranendra Narayan Saha, et al. (2007) was designed oral controlled release 
matrix tablets of lamivudine using hydroxypropyl methylcellulose (HPMC) as the 
retardant polymer and to study the effect of various formulation factors such as 
polymer proportion, polymer viscosity, and compression force on the in vitro release 
of drug. In vitro release studies revealed that the release rate decreased with increase 
in polymer proportion and viscosity grade. Increase in compression force was found 
to decrease the rate of drug release. Matrix tablets containing 60% HPMC 4000cps 
were found to show good initial release (26% in first hour) and extended the release 
up to 16 hours. Matrix tablets containing 80% HPMC 4000cps and 60% HPMC 
15000cps showed a first-hour release of 22% but extended the release up to 20 hours. 
Sudha T., et al. (2010) was developed for the analysis of lamivudine and 
abacavir in the combined dosage form (Abamune-L). The method depends on the 
application of simultaneous equation to resolve the interference due to spectral 
overlapping. The analytical signals were measured at 270 and 289 nm using 0.1N HCl 
as a solvent. Regression analysis of Beer's plot showed good correlation in a general 
concentration range of 5-30μg/ml with correlation coefficient (r=0.9995) for 
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lamivudine, whereas abacavir concentration range 5-30μg/ml with correlation 
coefficient (r=0.9992). The results of analysis have been validated statistically by 
repeatability and recovery studies. The results were found satisfactory and 
reproducible. The method was applied successfully for the estimation of lamivudine 
and abacavir simultaneously in tablet form without the interference of excipients. 
Swati Jain, et al. (2011)  was developed oral controlled release matrix tablets 
of lamivudine having different proportion of Guar gum (retardant polymer) and  
studied the effect of formulation factor such as polymer proportion on the in- vitro 
release. The prepared granules were evaluated such as angle of repose, loose bulk 
density, tapped bulk density and compressibility index and satisfactory results were 
obtained. Compressed tablets were also evaluated for uniformity of weight, content of 
active ingredient, thickness, friability, hardness, swelling, erosion behaviour and in-
vitro dissolution studies. All the formulations showed good results which were 
compliance with Pharmacopoeial standards. Matrix tablets containing 15% guar gum 
(Formulation F2) were found to show good initial release (21.34% in initial hour) and 
allowed sustained release up to 12 hours. 
Vyas S.P., et al. (2009) was developed for simultaneous estimation of 
lamivudine and silymarin. The method employs formation and solving of 
simultaneous equation using 270.9 nm and 326.4 nm as two analytical wavelengths. 
Both the drugs obey Beer‟s Law in the concentration ranges employed for this 
method. Accuracy and reproducibility of the proposed method was statistically 
validated by recovery studies. 
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   5. DRUG AND EXCIPIENTS PROFILE 
 
5.1. Drug profile:            (IP2007; Goodman and Gilman’s, 2001; http: // en. 
wikipedia.org/wiki/Lamivudine; http: //www.rxlist.com/epivir-drug. htm) 
5.1.1. Lamivudine: 
               Lamivudine is nucleoside reverse transcriptase inhibitor. 
Proprietary names : EPIVIR, 3TC. 
Molecular formula : C8H11N3O3S  
Molecular weight :  229.3  
Chemical name : 4-amino-1-[(2R, 5S)-2-(hydroxyl methyl)-1, 3-oxathiolan-5-
yl]-1, 2-dihydropyrimidin-2-one. 
Structural formula: 
 
 
Solubility               : It is soluble in water, sparingly soluble in methanol, and 
practically insoluble in acetone. 
Category                 : Anti retroviral drug. 
Dose                        : 150 mg per tablet twice daily. 
Melting point   :  172-178
0
C 
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pka :  4.26 
Tmax :   0.5 - 1.5 hours. 
Cmax :    1.0 μg/ml. 
Volume of distribution :   1.30 L/kg. 
Protein binding :  Less than 36% 
Biological half life         :  6 hours 
Bioavailability               :  86%. 
Description                    : Lamivudine is a white or almost white powder, odorless,     
           crystalline powder. 
                        Storage                          : It should be kept in a well closed container, protected from   
    light.   
Mechanism of action: 
Lamivudine is an analogue of cytidine. It can inhibit both types (1 and 2) of 
HIV reverse transcriptase and also the reverse transcriptase of hepatitis B. It is 
phosphorylated to active metabolites that compete for incorporation into viral DNA. 
They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain 
terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated 
nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage 
essential for DNA chain elongation, and therefore, the viral DNA growth is 
terminated. 
Pharmacokinetic: 
             Lamivudine is administered orally, and it is rapidly absorbed with a bio-
availability of over 80%. Some research suggests that lamivudine can cross the blood-
brain barrier. 
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Adverse effects: 
           The main adverse effect is severe abdominal or stomach pain, or feeling of 
fullness; nausea; tingling, burning, numbness, or pain in the hands, arms, feet, or legs; 
and vomiting.  
Drug interaction: 
 Trimethoprim / sulfamethoxazole (Bactrim, Septra) and vitamins increases the 
concentration of lamivudine in the body.   
Pregnancy: Use of lamivudine during pregnancy has not been adequately evaluated.  
Nursing mothers:  
It is not known whether lamivudine is secreted in breast milk. HIV infected 
mothers should not breast feed because of the potential risk of transmitting HIV to an 
infant that is not infected.  
Uses: 
 Lamivudine is used for the treatment of HIV infection, prevention of HIV in 
those accidentally exposed to HIV, and the treatment of the hepatitis B infection.  
How to use:  
            The recommended daily dose of lamivudine for adults is 300 mg once a day or 
150 mg twice a day. For children 3 months to 16 years of age, the recommended dose 
is 4 mg/kg, up to a maximum of 150 mg twice a day. The recommended dose of 
lamivudine may be different for patients with decreased kidney function. Some 
individuals may benefit from different doses of lamivudine. Individuals should always 
take lamivudine as directed by their doctors. Lamivudine may be administered 
without regard to meals.  
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Dosage forms: 
  This medicine comes in the following strengths and forms: 
 Lamivudine (Epivir-HBV) 100 mg tablets (for treating hepatitis B)  
 Lamivudine 150 mg tablets (for treating HIV and AIDS)  
 Lamivudine 300 mg tablets (for treating HIV and AIDS)  
 Lamivudine (Epivir-HBV) oral solution (for treating hepatitis B) -- 5 mg of 
lamivudine per ml.  
 Lamivudine oral solution (for treating HIV and AIDS) -- 10 mg of lamivudine 
per ml.  
5.2. Excipients profile:                                     
5.2.1. Hypromellose:                                          (Raymond C. R., et al., 2009) 
Nonproprietary names: 
 BP : Hypromellose  
 JP : Hydroxypropyl methylcellulose  
 PhEur : Hypromellosum 
USP : Hypromellose 
Synonyms: 
Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; Methocel; 
methylcellulose propylene glycol ether; methyl hydroxypropyl cellulose; Metolose; 
Tylopur. 
Chemical name and CAS registry number: 
Cellulose 2- hydroxypropyl methyl ether [9004-65-3] 
Molecular weight: 
Molecular weight is approximately 10,000-1,500,000.  
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Structural formula: 
 
                            Where R is H, CH3, or CH3CH (OH) CH2 
Functional category: 
Coating agent; film-former; rate-controlling polymer for sustained release; 
stabilizing agent; suspending agent; tablet binder and viscosity increasing agent. 
Applications in pharmaceutical formulation or technology: 
Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical 
formulations. In oral products, hypromellose is primarily used as a tablet binder, in 
film-coating, and as matrix for use in extended-release tablet formulations.  
Concentrations between 2% and 5% w/w may be used as a binder in either wet- or 
dry-granulation processes.  
High-viscosity grades may be used to retard the release of drugs from a matrix 
at levels of 10-80% w/w in tablets and capsules. Depending upon the viscosity grade, 
concentrations of 2-20% w/w are used for film-forming solutions to film-coat tablets. 
 Lower-viscosity grades are used in aqueous film-coating solutions, while 
higher-viscosity grades are used with organic solvents. Hypromellose at 
concentrations between 0.45-1.0% w/w may be added as a thickening agent to 
vehicles for eye drops and artificial tear solutions.  
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Description: 
Hypromellose is an odorless and tasteless, white or creamy-white fibrous or 
granular powder. 
Melting point:  
 Browns at 190-200°C; chars at 225-230°C, glass transition temperature is 170-
180°C. 
Moisture content:   
 Hypromellose absorbs moisture from the atmosphere; the amount of water 
absorbed depends upon the initial moisture content and the temperature and relative 
humidity of the surrounding air.  
Solubility: 
 Soluble in cold water, forming a viscous colloidal solution; practically 
insoluble in chloroform, ethanol (95%) and ether but  its soluble in mixtures of 
ethanol and dichloromethane, mixtures of methanol and dichloromethane, mixtures of 
water and alcohol. Certain grades of hypromellose are soluble in aqueous acetone 
solutions, mixtures of dichloromethane and propan-2-ol and other organic solvents. 
Viscosity (dynamic):  
           A wide range of viscosity types are commercially available. Aqueous 
solutions are most commonly prepared, although hypromellose may also be dissolved 
in aqueous alcohols such as ethanol and propan-2-ol provided the alcohol content is 
less than 50% w/w.  
Stability and storage conditions: 
Hypromellose powder is a stable material, although it is hygroscopic after 
drying. Solutions are stable at pH 3-11. Increasing temperature reduces the viscosity 
of solutions. Hypromellose undergoes a reversible sol-gel transformation upon 
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heating and cooling, respectively. The gel point is 50-90°C, depending upon the grade 
and concentration of material. 
5.2.2. Ethyl cellulose:                                                   (Raymond C. R., et al., 2009) 
Nonproprietary names: 
           BP : Ethylcellulose                   
           PhEur   : Ethylcellulosum 
           USP : Ethylcellulose  
Synonyms: 
            Aquacoat ECD; Aqualon; Ethocel. 
Chemical name and CAS registry number: 
            Cellulose ethyl ether [9004-57-3]   
Description:  
             It is a tasteless, free flowing, white to light tan colored   powder. 
Empirical formula and molecular weight:   
 Ethyl cellulose with complete ethoxyl substitution (DS = 3) is C12H23O6 
(C12H22O5) nC12H23O5 where n can vary to provide a wide variety of molecular 
weights. Ethyl cellulose, an ethyl ether of cellulose, is a long-chain polymer of β-
anhydroglucose units joined together by acetyl linkages. 
Structural formula:  
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Functional Category:  
           Coating agent; flavoring fixative; tablet binder; tablet filler; viscosity- 
increasing agent.                                                                                                                                                                                
Solubility:  
            Insoluble in water, glycerin, propylene glycol, ethyl cellulose that contains not 
less than 46.5% of ethoxyl group is freely soluble in chloroform, ethanol 95%, ethyl 
acetate, methanol and toluene.   
Viscosity:   
            The viscosity of ethyl cellulose is determined at 25
o
C by employing 5%w/w 
ethyl cellulose solubilized in a solvent ratio of 80% toluene: 20% ethanol. If 
increasing the viscosity of ethyl cellulose solution with an increase in ethyl cellulose 
concentration.  
Applications in pharmaceutical formulation or technology: 
            Ethyl cellulose by itself forms a water insoluble coating for tablets and 
granules. It can improve the stability of a formulation. Modified release dosage form 
produced by incorporating of ethyl cellulose as a matrix material. 
            High viscosity grades of ethyl cellulose are used in microencapsulation 
process. For topical application it‟s used as a thickening agent in creams and lotions.  
            Ethyl cellulose it has been used as an agent for release the active compounds 
from oral appliances. Ethyl cellulose coated granules have the ability to absorb 
pressure and it will protect the coating layer from cracking during compression. 
Stability:  
        It is chemically resistant to alkalis both dilute and concentrated but           
more sensitive to acidic materials than cellulose esters.     
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5.2.3. Methyl cellulose:                                                 (Raymond C. R., et al., 2009) 
Nonproprietary names: 
           BP : Methylcellulose                   
           PhEur   : Methylcellulosum 
           USP : Methylcellulose  
Synonyms: 
            Benecel; Culminal MC; E461; Methocel; Metolose. 
Chemical name and CAS registry number: 
           Cellulose methyl ether [9004-67-5] 
Description:  
 Methylcellulose occurs as a white, fibrous powder or granules. It is practically 
odorless and tasteless.  
Empirical formula and molecular weight:   
 Methylcellulose is a long-chain substituted cellulose in which approximately 
27–32% of the hydroxyl groups are in the form of the methyl ether. The various 
grades of methylcellulose have degrees of polymerization in the range 50–1000, with 
molecular weights (number average) in the range 10,000–2,20,000 Da. The degree of 
substitution of methylcellulose is defined as the average number of methoxyl (CH3O) 
groups attached to each of the anhydro glucose units along the chain. The degree of 
substitution also affects the physical properties of methylcellulose, such as its 
solubility. 
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Structural formula:  
 
Functional Category:  
 Coating agent; emulsifying agent; suspending agent; tablet and capsule 
disintegrant; tablet binder; viscosity increasing agent.                                                                                                                                                                     
Solubility:  
 Practically insoluble in acetone, methanol, chloroform, ethanol (95%), ether, 
saturated salt solutions, toluene, and hot water. Soluble in glacial acetic acid and in a 
mixture of equal volumes of ethanol and chloroform. In cold water, methylcellulose 
swells and disperses slowly to form a clear to opalescent, viscous, colloidal 
dispersion. 
Viscosity:   
            Various grades of methylcellulose are commercially available that vary in 
their degree of polymerization. Aqueous solutions at concentrations of 2% w/v will 
produce viscosities between 5 and 75,000 mPas. Individual grades of methylcellulose 
have a stated, narrowly defined viscosity range measured for a 2% w/v solution. The 
viscosity of solutions may be increased by increasing the concentration of 
methylcellulose. Increased temperatures reduce the viscosity of solutions until gel 
formation occurs at 50–60°C. The process of thermogelation is reversible, with a 
viscous solution being reformed on cooling. 
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Applications in pharmaceutical formulation or technology: 
In tablet formulations, low- or medium-viscosity grades of methylcellulose are 
used as binding agents, the methylcellulose being added either as a dry powder or in 
solution. High viscosity grades of methylcellulose may also be incorporated in tablet 
formulations as a disintegrant. Methylcellulose may be added to a tablet formulation 
to produce sustained-release preparations. 
Tablet cores may also be spray-coated with either aqueous or organic solutions 
of highly substituted low-viscosity grades of methylcellulose to mask an unpleasant 
taste or to modify the release of a drug by controlling the physical nature of the 
granules. Methylcellulose coats are also used for sealing tablet cores prior to sugar 
coating. 
Low-viscosity grades of methylcellulose are used to emulsify olive, peanut, 
and mineral oils. They are also used as suspending or thickening agents for orally 
administered liquids, methylcellulose commonly being used in place of sugar-based 
syrups or other suspension bases. Methylcellulose delays the settling of suspensions 
and increases the contact time of drugs, such as antacids, in the stomach. 
High-viscosity grades of methylcellulose are used to thicken topically applied 
products such as creams and gels. 
In ophthalmic preparations, a 0.5–1.0% w/v solution of a highly substituted, 
high-viscosity grade of methylcellulose has been used as a vehicle for eye drops. 
However, hypromellose based formulations are now preferred for ophthalmic 
preparations. 
Therapeutically, methylcellulose is used as a bulk laxative; it has also been 
used to aid appetite control in the management of obesity, but there is little evidence 
supporting its efficacy. 
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Stability and storage:   
   Methylcellulose powder is stable, although slightly hygroscopic. The bulk 
material should be stored in an airtight container in a cool, dry place. 
5.2.4. Cellulose, Microcrystalline:                                  (Raymond C. R., et al., 2009) 
Nonproprietary names: 
BP : Microcrystalline cellulose 
JP : Microcrystalline cellulose 
PhEur : Cellulosum microcristallinum 
USPNF : Microcrystalline cellulose 
Synonyms: 
 Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG; crystalline cellulose; 
E460; Emcocel; Ethispheres; Fibrocel; Pharmacel; Tabulose; Vivapur. 
Chemical name and CAS registry number: 
Cellulose [9004-34-6] 
Molecular weight: 
Approximately 36,000 
Structural formula: 
 
 
Functional category: 
Adsorbent; suspending agent; tablet and capsule diluents; tablet disintegrant. 
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Description: 
Microcrystalline cellulose is purified, partially depolymerized cellulose that 
occurs as a white, odorless, tasteless, crystalline powder composed of porous 
particles. It is commercially available in different particle sizes and moisture grades 
that have different properties and applications. 
Moisture content: 
 Typically less than 5% w/w. However, different grades may contain varying   
amounts of water. Microcrystalline cellulose is hygroscopic.  
Solubility:  
 Slightly soluble in 5% w/v sodium hydroxide solution, practically insoluble in 
water, dilute acids and most organic solvents. 
Applications in pharmaceutical formulation or technology: 
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as 
binder/diluents in oral tablet and capsule formulations where it is used in both wet-
granulation and direct compression processes. In addition to its use as binder/diluents, 
microcrystalline cellulose also has some lubricant and disintegrant properties that 
make it useful in tableting. 
         Use                                                           Concentration (%) 
 Adsorbent                                                                20–90 
 Antiadherent                                                             5–20 
 Capsule binder/diluent                                             20–90 
 Tablet disintegrant                                                     5–15 
 Tablet binder/diluent                                                 20–90 
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Stability and storage conditions: 
 Microcrystalline cellulose is a stable though hygroscopic material. The bulk 
material should be stored in a well-closed container in a cool, dry place. 
5.2.5. Povidone:                                                                (Raymond C. R., et al., 2009) 
Nonproprietary names: 
  BP       : Povidone      
            JP        : Povidone            
PhEur  : Povidonum                         
USP    : Povidone 
Synonyms: 
 E1201;  Kollidon; Plasdone; poly [1-(2-oxo-1-pyrrolidinyl) ethylene]; 
polyvidone, polyvinyl pyrrolidone; 1-vinyl-2-pyrrolidinone polymer. 
Chemical name and CAS registry number: 
1-Ethenyl-2-pyrrolidinone homopolymer [9003-39-8] 
Empirical formula and molecular weight 
(C6H9NO)n  and 2500-30,00,000 respectively. 
 
       K-value                                         Approximate molecular weight 
12                                                             2,500 
15                                                             8,000 
17                                                            10,000 
25                                                            30,000 
30                                                            50,000 
60                                                           4,00,000 
                        90                                                          10,00,000 
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Structural formula: 
 
 
Functional category:  
 Disintegrant; dissolution aid; suspending agent; tablet binder. 
Description:  
 Povidone occurs as a fine, white to creamy-white colored, odorless, 
hygroscopic powder. 
Moisture content:  
            Povidone is very hygroscopic, significant amounts of moisture being absorbed 
at low relative humidity.  
Solubility:   
            Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol and 
water; practically insoluble in ether, hydrocarbons and mineral oil.  
Viscosity (dynamic): 
           The viscosity of aqueous povidone solutions depends on both the concentration 
and the molecular weight of the polymer employed.     
Applications in pharmaceutical formulation or technology: 
Although povidone is used in a variety of pharmaceutical formulations, it is 
primarily used in solid-dosage forms. In tableting, povidone solutions are used as 
binders in wet granulation processes. Povidone is also added to powder blends in the 
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dry form and granulated in situ by the addition of water, alcohol or hydro alcoholic 
solutions.  
        Use                                                                     Concentration (%) 
Carrier for drugs                                                                  10–25 
Dispersing agent                                                                 Up to 5 
Eye drops                                                                              2–10 
Suspending agent                                                                Up to 5 
Tablet binder, tablet diluents or coating agent                      0.5–5 
Stability and storage conditions: 
 Povidone darkens to some extent on heating at 150°C, with a reduction in 
aqueous solubility. It is stable to a short cycle of heat exposure around 110–130°C; 
steam sterilization of an aqueous solution does not alter its properties. 
5.2.6. Magnesium stearate:                                              (Raymond C.R., et al., 2009) 
Nonproprietary names: 
BP : Magnesium stearate 
JP : Magnesium stearate 
PhEur : Magnesii stearas 
USPNF : Magnesium stearate  
Synonyms:    
          Magnesium octa decanoate, Magnesium salt. 
Chemical name and CAS registry number 
Octa decanoic acid magnesium salt [557-04-0] 
Functional category : Tablet and capsule lubricant 
Empirical formula :   C36H70MgO4 
Molecular weight :  591.3 
Lamivudine Sustained Release Matrix Tablets    DRUG AND EXCIPIENTS PROFILE 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur.  72 
 
Structure: 
                                         CH3 (CH2)16 COO                           
                                                                                      Mg    
                                         CH3 (CH2)16 COO 
Description: 
           It is a fine, white, precipitated or milled, impalpable powder of low bulk 
density and having a faint odor of stearic acid, characteristic taste.  
 Solubility: 
          It is insoluble in water, ethanol and ether. It can slightly soluble in warm 
ethanol and benzene.        
 Stability and storage conditions: 
  Stable, Store in a well closed container in a cool, dry place.                    
5.2.7. Talc:                                                                        (Raymond C. R., et al., 2009) 
Nonproprietary names: 
BP : Purified talc 
JP : Talc 
PhEur : Talcum 
USPNF : Talc 
Synonyms: 
 Purified chalk, altalc, powdered talc and soapstone 
Chemical name and CAS registry number: 
Talc [14807-96-6] 
Description: 
            A very fine, white to grayish white, impalpable, odorless crystalline powder,  
Unctuous, adheres readily to skin, soft to touch and free from granules. 
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Empirical formula:   
 Mg6 (Si2O5)4(OH)4 
Functional category: 
            Tablet, capsule it can use as a lubricant and diluents. During compression used 
as glidant and anticaking agent. 
Solubility:    
 Insoluble in water, organic solvents, dilutes acids and alkalis. 
Storage conditions:  
 Stable, Preserve in a well-closed container in a cool, dry place. 
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                       6. MATERIALS AND EQUIPMENTS 
 
6.1. Materials used: 
Table 6.1: List of materials with source 
S.No. Name of Ingredients Name of supplier 
1 Lamivudine Shasun pharmaceuticals, Puducherry. 
2 HPMC K4M Tristar formulations Pvt. Ltd., Puducherry. 
3 Ethyl cellulose Tristar formulations Pvt. Ltd., Puducherry. 
4 Methyl cellulose Shasun pharmaceuticals, Puducherry. 
5 Microcrystalline cellulose Nickon laboratories Pvt. Ltd., Puducherry. 
6 Polyvinyl pyrrolidone K30 Nickon laboratories Pvt. Ltd., Puducherry. 
7 Magnesium stearate Loba chemie Pvt.Ltd., Mumbai. 
8 Talc Loba chemie Pvt.Ltd., Mumbai. 
9 Hydrochloric acid S d fine-chem limited, Mumbai. 
10 Methanol Qualigens fine chemicals, Mumbai. 
11 Acetone Loba chemie Pvt.Ltd., Mumbai. 
12 Sodium hydroxide S d fine-chem limited, Mumbai. 
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6.2. Equipments used: 
Table 6.2: List of equipments with model/make 
S.No. Equipment Model/ Make 
1 Electronic balance Shimadzu BL-220H, Japan. 
2 Bulk density apparatus Indolabs VTAP/MATIC-II, Chennai. 
3 Standard sieves Jayant scientific, India. 
4 Hot air oven Precision scientific Co., Chennai. 
5 
Sixteen punch tablet compression 
machine 
Cadmach, Ahmadabad, India. 
6 Friability apparatus Veego scientific VFT-DV, Mumbai. 
7 Hardness tester Monsanto 
8 Vernier caliper Indolabs, Mitutoyo. 
9 Humidity chamber Labtech, Ambala. 
10 
USP dissolution test apparatus 
Type I 
Veego scientific VDA-8DR, Mumbai. 
11 UV-Visible spectrophotometer 
Elico-SL 159 UV-Visible 
spectrophotometer, Japan. 
12 FTIR spectrophotometer Shimadzu, Japan. 
13 Differential scanning calorimeter Shimadzu, Japan. 
 
 
 
 
  
 
 
 
 
EXPERIMENTAL 
WORK 
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7. EXPERIMENTAL WORK 
7.1. Preformulation study: 
 Preformulation testing is an investigation of physical and chemical properties 
of a drug substance alone. It is the first step in rational development of dosage form. 
7.1.1. Identification of drug: 
7.1.1.1. Identification by FTIR spectroscopy:     (IP, 2007; Skoog D.A., et al., 2004)     
 Lamivudine discs were prepared by pressing the lamivudine with potassium 
bromide and the spectra ranges between 4000 to 400 cm
-1
 was obtained under the 
operational conditions. The absorption maximums in spectrum obtained with the 
substance being examined correspond in position and relative intensity to those in the 
reference spectrum.  
7.1.1.2. Identification by melting point:                             (IP, 2007)                                                
 
Melting point of the drug was determined by capillary tube method. 
7.1.2. Physicochemical parameters:
 
7.1.2.1. Organoleptic properties:     (Lachman L., et al., 1991; Banker G.S., et al., 
2009)   
The color, odor and taste of the drug were recorded using descriptive 
terminology. 
7.1.2.2. Solubility study:                                                        (IP, 2007)
 
It is important to know about solubility characteristic of a drug in aqueous 
system, since they must possess some limited aqueous solubility to elicit a therapeutic 
response. The solubility of drug was recorded by using various descriptive 
terminology specified in Indian Pharmacopoeia, 2007. 
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7.1.3. Analytical methods:  
7.1.3.1. Determination of absorption maximum in 0.1 N HCl:   (Sudha T., et al., 
2010)              
 A stock solution of lamivudine was prepared by dissolving 100 mg of drug in 
0.1 N HCl and final volume was made to 100 ml. From the stock solution, 1 ml was 
pipettted out into 100 ml volumetric flask to obtain concentration of 10µg/ml. The 
solution was scanned in the range of wavelength of 200 to 400 nm region on 
shimadzu- 1700 pharmaspec UV- Visible spectrophotometer.  
7.1.3.2. Determination of absorption maximum in pH 6.8 phosphate buffer:     
(Sudha T., et al., 2010) 
 A stock solution of lamivudine was prepared by dissolving 100 mg of drug in 
pH 6.8 and final volume was made to 100 ml. From the stock solution, 1 ml was 
pipettted out into 100 ml volumetric flask to obtain concentration of 10µg/ml. The 
solution was scanned in the range of wavelength of 200 to 400 nm regions on 
shimadzu- 1700 pharmaspec UV-Visible spectrophotometer. 
7.1.3.3. Preparation of standard curve of lamivudine in 0.1N HCl:       (Sudha T., 
et al., 2010)  
            A stock solution of lamivudine was prepared by dissolving 100 mg of drug in 
0.1 N HCl and final volume was made to 100 ml to give a solution concentration 1000 
µg/ml. From the stock solution, 10 ml was pipettted out into 100 ml volumetric flask 
to obtain concentration of 100µg/ml. From the standard stock solution of lamivudine, 
appropriate aliquots of 2.5, 5.0, 7.5, 10.0, 12.5 and 15.0 ml were pipetted out into 50 
ml volumetric flask and final volume was made with 0.1 N HCl. To obtained 
concentration of 5, 10, 15, 20, 25 and 30 µg/ml. Absorbance spectra of each solution 
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against 0.1 N HCl as blank were measured at 281 nm using Elico-SL 159 UV-Visible 
spectrophotometer.   
7.1.3.4. Preparation of standard curve of lamivudine in pH 6.8 phosphate buffer: 
(Sudha T., et al., 2010) 
            A stock solution of lamivudine was prepared by dissolving 100 mg of drug in 
pH 6.8 and final volume was made to 100 ml to give a solution concentration 1000 
µg/ml. From the stock solution, 10 ml was pipettted out into 100 ml volumetric flask 
to obtain concentration of 100µg/ml. From the standard stock solution of lamivudine 
appropriate aliquots of 2.5, 5.0, 7.5, 10.0, 12.5 and 15.0 ml were pipetted out into 50 
ml volumetric flask and final volume was made with pH 6.8. To obtained 
concentration of 5, 10, 15, 20, 25 and 30 µg/ml. Absorbance spectra of each solution 
against pH 6.8 as blank were measured at 271.5 nm using Elico-SL 159 UV-Visible 
spectrophotometer.  
  7.1.3.5. Determination of Percentage purity of Drug:     (Ravichandran V., et al., 
2009)  
           An accurately weighed 100 mg of lamivudine was dissolved in 100 ml of pH 
6.8 phosphate buffer followed by mixing for 10 minutes. From the stock solution, 10 
ml was pipettted out into 100 ml volumetric flask to obtain concentration of 
100µg/ml.  The solution was filtered through a 0.45μ membrane filter. From the 
above solution, aliquots of 0.6 ml were transferred to 10 ml volumetric flasks and 
final volume was made to 10 ml with pH 6.8 phosphate buffer and the absorbance of 
resultant solution was measured by using Elico-SL 159 UV-Visible 
spectrophotometer at 271.5 nm using pH 6.8 phosphate buffer as blank. 
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7.1.4. Determination of drug-polymer compatibility:                 (Aulton M.E., 2007) 
 Differential scanning calorimetry, Fourier transforms infrared spectroscopy 
studies were used for the evaluation of physicochemical compatibility and interaction, 
which helps in the prediction of interaction of the drug and polymers. Each polymer 
used in the formulations was blended with the drug levels that are realistic with 
respect to the final dosage form. Each polymer was thoroughly blended with drug to 
increase drug- polymer molecular contacts to accelerate the reactions if possible. 
7.1.4.1. Fourier transform infrared spectroscopy:           (Althaf A.S., et al., 2010; 
Raju M.,et al., 2010; Silverstein R.M., 2003)         
            FTIR studies are very helpful in the evaluation of drug polymer interaction 
studies. If there is any incompatibility between the drug and polymer, these can be 
predicted by changes in the functional peaks. Infrared spectrum of lamivudine was 
determined on Fourier transform infrared spectrophotometer using potassium bromide 
dispersion method. The base line correction was done using dried potassium bromide. 
Then the spectrum of dried mixture of drug and various polymers were thoroughly 
mixed with potassium bromide. The crushed powders were compressed using a 
hydraulic compactor at approximately 20,000 pounds under vacuum for 3 minutes. 
FTIR instrument were performed under nitrogen atmosphere at a flow rate of 50 
standard cubic feet per hour. Spectral scanning was conducted from 4000 to 400 cm
-1
 
at a resolution of 4 cm
-1
 by using Shimadzu (Japan) FTIR spectrophotometer.  
7.1.4.2. Differential scanning calorimetry:      (Raju M.,et al., 2010; Willard H.H., 
et al., 2008) 
            Any possible drug polymer interaction can be studied by thermal analysis. The 
DSC analysis of pure drug, drug + HPMC K4M, drug + methyl cellulose and drug + 
ethyl cellulose were carried out using Shimadzu to evaluate any possible drug-
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polymer interaction. The 2 mg sample were heated in a hermetically sealed aluminum 
pans in the temperature range of 25-300ºC at heating rate of 10ºC /min under nitrogen 
flow of 30 ml/min.  
7.1.5. Formulation of lamivudine sustained release matrix tablets:     (Swati jain, 
et al., 2011)                                                
  All the ingredients mentioned in Table 7.1 were pre-weighed and passed 
through mesh #60 separately. The drug and polymer were blended first in mortar and 
pestle then the remaining ingredients are added in that and blended for 15 minutes 
and the blend is finally passed through mesh #20 and used for evaluation of flow 
characteristic. 
                          Table 7.1: Composition of lamivudine SR matrix tablets 
Ingredients LF1 LF2 LF3 LF4 LF5 LF6 LF7 LF8 LF9 
Lamivudine 200 200 200 200 200 200 200 200 200 
HPMC K4M 40 80 120 - - - - - - 
Methyl cellulose - - - 40 80 120 - - - 
Ethyl cellulose - - - - - - 40 80 120 
Microcrystalline- 
cellulose PH 102 
128 88 48 128 88 48 128 88 48 
Polyvinyl 
pyrrolidone-k30 
20 20 20 20 20 20 20 20 20 
Magnesium 
stearate 
4 4 4 4 4 4 4 4 4 
Talc 8 8 8 8 8 8 8 8 8 
Total weight 400 400 400 400 400 400 400 400 400 
All the quantities are expressed as mg per tablet. 
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7.1.6. Evaluation of pre-compression blend: 
7.1.6.1. Angle of repose:                                          (Lachman L., et al., 1991) 
The angle of repose was determined by the funnel method. An accurately 
weighed powder was taken in a funnel. The height of the funnel was adjusted in such 
a way that the tip of the funnel just touched the apex of the heap of the powder. The 
powder was allowed to flow through the funnel freely onto the surface. The diameter 
of the powder cone was measured. The angle of repose was calculated using the 
following equation. 
                                                          ( )  
 
 
 
Where „h‟ and „r‟ are the height and radius respectively of the powder cone. 
Table 7.2: Standard values of angle of repose (°) 
S. No. Flowability  Angle of repose  
1 Excellent <25 
2 Good 25-30 
3 Passable* 30-40 
4 Poor 37-45 
5 Very poor >45 
          * Adding glidant for improving flow 
7.1.6.2. Loose bulk density:                                       (Lachman L., et al., 1991)
 
An accurately weighed powder blend from each formula was lightly shaken to 
break any agglomerates formed and it was introduced in to a measuring cylinder. The 
volume occupied by the powder was measured which gave bulk volume. The loose 
bulk density of powder blends was determined using the following formula. 
Loose bulk density = Total weight of powder / Total volume of powder 
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7.1.6.3. Tapped bulk density:                                       (Lachman L., et al., 1991) 
An accurately weighed powder blend from each formula was lightly shaken to 
break any agglomerates formed and it was introduced into a measuring cylinder. The 
measuring cylinder was tapped until no further change in volume was noted which 
gave the tapped volume. The tapped bulk densities of powder blends were determined 
using the following formula. 
   Tapped bulk density= Total weight of powder / Total volume of tapped powder 
7.1.6.4. Hausner’s ratio:                                                    (Aulton M.E., 2007) 
It is related to interparticulate friction and could be used to predict powder 
flow properties.   Hausner‟s ratio was determined by following equation,    
Hausner’s Ratio = Tapped bulk density / Loose bulk density 
  A Hausner ratio less than 1.25 indicates good flow while greater than 1.5 
indicates poor flow. 
7.1.6.5. Carr’s compressibility index:                             (Aulton M.E., 2007) 
It is a simple index that can be determined on small quantities of powder. The 
compressibility indices of the powder blends was determined using following 
formula, 
Carr’s compressibility index (%) = [(TBD-LBD)/ TBD] x100 
Relationship between % compressibility and flowability is shown in the table 7.3.  
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Table 7.3: Standard values of Carr‟s index 
S. No. Carr’s index Type of flow 
1 5-15 Excellent 
2 12-16 Good 
3 18-21 Fair to passable 
4 23-35 Poor* 
5 33-38 Very poor* 
6 >40 Extremely poor* 
* May be improved by glidant 
7.2. Preparation of SR Matrix Tablets:      (Potu Apparao, et al., 2011)  
Direct compression method: 
All the ingredients metioned in Table 7.1 were passed through Sieve no. 60 
mesh separately and collected. Ingredients were mixed in geometrical order and 
thoroughly mixed for 15 minutes to get a uniform mixture and the blend is finally 
passed through mesh #20. Talc and magnesium stearate were added to the powder 
mixture and compressed on a 16- station rotary tablet compression machine using 
11mm round, biconcave punches.   
The drug polymer ratio was developed to adjust drug release as per theoretical 
release profile and to keep total weight of tablet constant for all the fabricated batches 
under experimental conditions of preparations. The total weight of the matrix tablets 
was 400 mg with different drug polymer ratios like 1:0.2, 1:0.4, and 1:0.6. The 
various polymers used were hydroxypropyl methylcellulose (HPMC K4M), methyl 
cellulose and ethyl cellulose. 
In the formulations prepared, the release retardants included were 
hydroxypropyl methylcellulose (HPMC K4M), ethyl cellulose and methyl cellulose. 
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Microcrystalline cellulose (MCC) is used as diluent. Magnesium stearate 1% and talc 
2 % were used as lubricant and glidant.  
7.3. Evaluation of lamivudine sustained release matrix tablets:  
7.3.1. Appearance:                                                  (Lachman L., et al., 1991) 
The tablets were visually observed for capping, chipping and lamination. 
7.3.2. Dimension (Thickness and Diameter):          (Lachman L., et al., 1991)                          
 The thickness and diameter of tablets were important for uniformity of tablet 
size. The thickness and diameter of the tablets was determined by using Vernier 
caliper. Ten tablets from each type of formulation were used and average values were 
calculated.  
7.3.3. Tablet hardness:                                          (Lachman L., et al., 1991) 
For each formulation, the hardness of 10 tablets was determined using the 
Monsanto hardness tester. The tablet was held along its oblong axis in between the 
two jaws of the tester. At this point, reading should be zero kg/cm
2
. Then constant 
force was applied by rotating the knob until the tablet fractured. The value at this 
point was noted in kg/cm
2
.  
7.3.4. Percent friability:                                           (Lachman L., et al., 1991) 
Friability is the measure of tablet strength. This test subjects a number of 
tablets to the combined effect of shock abrasion by utilizing a plastic chamber which 
revolves at a speed of 25 rpm, dropping the tablets to a distance of 6 inches in each 
revolution. A sample of pre weighed tablets was placed in Roche friabilator which 
was then operated for 100 revolutions. The tablets were then dedusted and reweighed. 
A loss of less than 1 % in weight is generally considered acceptable. Percent friability 
(% F) was calculated as follows.  
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7.3.5. Weight variation:                                  (IP, 2007; Lachman L., et al., 1991) 
To find out weight variation 20 tablets of each formulation were weighed 
individually using an electronic balance, average weight was calculated and 
individual tablet weight was then compared with average value to find the deviation 
in weight. The test was performed according to the official method. 
Weight variation importance during tablets compression section, each and 
every time intervals we must check the weight of tablet. If we are not maintaining the 
weight variation means it will give the deviation of drug content as well as yield of 
tablets.  
 Table 7.4: Specifications of % weight variation allowed in tablets as per Indian 
Pharmacopoeia 
S. No. Average weight of tablets (mg) 
Maximum percent deviation 
allowed (%) 
1 80 or less 10 
2 More than 80 but less than 250 7.5 
3 More than 250 5 
 
7.3.6. Drug content:                    (Swati jain, et al., 2011; http://www.who.int)  
The drug content in each formulation was determined by triturating 20 tablets 
and powder equivalent to 100 mg of lamivudine was transferred into a 100 ml 
standard volumetric flask. Then added 50ml of pH 6.8 phosphate buffer solution. It 
was gently shaken for 15 minutes. Then made upto the mark with pH 6.8 phosphate 
buffer solution. The solution was filtered through a whatmann filter paper, diluted 
suitably and the absorbance of resultant solution was measured by using Elico-SL 159 
UV-Visible spectrophotometer at 271.5 nm using pH 6.8 phosphate buffer as blank. 
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7.3.7. In vitro release studies:                                     (Potu Apparao., et al., 2011) 
The release rate of lamivudine from matrix tablets was determined using 
United States Pharmacopoeia dissolution testing apparatus I (Basket method; Veego 
Scientific VDA-8DR, Mumbai, India). The dissolution test was performed at 100 rpm 
using 900 ml of pH 1.2  for the first 2 hrs and phosphate buffer pH 6.8 from 2-12 hrs 
at 37 ± 0.5°C. A sample (5 ml) of the solution was withdrawn from the dissolution 
apparatus hourly and the samples were replaced with fresh dissolution medium. The 
samples were filtered through a 0.45μ membrane filter and diluted suitably. 
Absorbance of these solutions was measured at 271.5 nm using Elico-SL 159 UV-
Visible spectrophotometer. For each formulation, the experiments were carried out in 
triplicate. The release data were analyzed to study the release kinetics using zero 
order, first order and matrix, korsmeyer-peppas equations by using PCP disso V3 
software. 
7.3.8. Kinetics of in vitro drug release:   (Brahmankar D.M. and Jaiswal S.B., 2009; 
Harris S.M., et al., 2006) 
To study the release kinetics of in vitro drug release, the data was applied to 
kinetic models such as zero order, first order, higuchi and korsmeyer- Peppas. 
 Zero order 
 
Where     K0 - Zero-order rate constant expressed in units of concentration/time   
                 t - Time in hrs. 
 First order 
 
Where   C0 - Initial concentration of drug, 
               K - First order constant and t - Time in hrs.  
C = K0t                                                                                                               
LogC = LogC0 – Kt / 2.303                                                                             
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 Higuchi 
 
Where   Qt - Amount of the release drug in time t, 
               K- Kinetic constant and t- is time in hrs 
 Korsmeyer Peppas 
 
Where, Mt - represents amount of the released drug at time t,  
           M∞- Overall amount of the drug (whole dose) released after 12 hrs  
           K- Diffusion characteristic of drug/ polymer system constant  
           n- Diffusion exponent that characterizes the mechanism of release of drug.  
Table 7.5: Diffusion exponent and solute release mechanism 
Diffusion exponent (n) Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45<n <0.89 Anomalous (non-Fickian) diffusion 
0.89 Case-II transport 
n>0.89 Super case-II transport 
 
7.4. Stability study:        (Carstensen J.T., et al., 2008; Manavalan R., et al., 2008)  
The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light, enabling 
recommended storage conditions, re-test periods and shelf-lives. Generally, the 
observation of the rate at which the product degrades under normal room temperature 
requires a long time. To avoid this undesirable delay, the principles of accelerated 
stability studies are adopted.  
Qt = Kt
1/2
                                                                                                          
Mt / M∞ = Kt n                                                                                                                                                                                                    
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ICH specifies the length of study and storage conditions 
 Long-Term Testing: 25 C ± 2 C at 60% RH ± 5% for 12 Months  
 Accelerated Testing: 40 C ± 2 C at 75% RH ± 5% for 6 Months  
In present study the selected formulation LF3 exposure  up to 3 months 
stability studies at accelerated condition (40 C ± 2 C
 
at 75% RH ± 5% RH) to find 
out the effect of aging on hardness, drug content and in vitro drug release.  
Stability studies were carried out at accelerated condition (40 C ± 2 C
                    
at 75% RH ± 5% RH) for the optimized formulation LF3. The matrix                  
tablets were stored at 40 C ± 2 C at 75% RH ± 5% RH for accelerated         
temperature in closely packed with aluminium foil for 3 months. The                
samples were withdrawn after periods of 1
st
 month, 2
nd
 month and 3
rd
 month. The 
samples were analyzed for its hardness, drug content and in vitro drug release.   
  
 
 
 
 
RESULTS 
AND  
DISCUSSION
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                        8. RESULTS AND DISCUSSION 
 
8.1. Preformulation parameters: 
8.1.1. Identification of drug: 
8.1.1.1. Identification by FTIR spectroscopy: 
The FTIR spectrum of lamivudine was shown in Figure 8.1 and the 
interpretations of FTIR frequencies were showed in Table 8.1. 
 
Figure 8.1: FTIR spectrum of lamivudine 
 Interpretation of FTIR Spectrum: 
Major functional groups present in lamivudine shows characteristic peaks in 
FTIR spectrum. Table 8.1 shows peaks observed at different wave numbers and the 
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functional group associated with these peaks.
 
The major peaks are identical to 
functional group of lamivudine. Hence, the sample was confirmed as lamivudine. 
Table 8.1: Characteristic frequencies in FTIR spectrum of lamivudine 
Wave No.(cm
-1
) Functional group 
3328.23 O-H stretching 
3076.51 N-H stretching 
2840.23 C-H stretching 
1653.02 C=O stretching 
1613.48 C=N stretching 
1521.86 C=C stretching 
1287.51 C-N stretching 
1088.84 C-O stretching 
852.55 C-C stretching 
786.97 C-S stretching 
 
8.1.1.2. Melting point: 
Melting point of lamivudine sample was found to be 174
0
C. The reported 
melting point for lamivudine was in range of 172 to 178
0
C. Hence, experimental 
values are in good agreement with official values. 
8.1.2. Physicochemical parameters of drug: 
8.1.2.1. Organoleptic properties: 
Odour     :  Odorless  
Colour    :  A White (or) almost white powder 
Taste    :  Bitter taste 
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8.1.2.2. Solubility study: 
Table 8.2: Solubility of lamivudine in different solvents 
 
8.1.3. Analytical methods:
 
8.1.3.1. Determination of absorption maximum in 0.1 N HCl: 
                   The absorption maximum for lamivudine was found to be 281 nm. 
 
Figure 8.2: λ max observed for lamivudine in 0.1N HCl 
Name of solvents Solubility 
Distilled water   Soluble 
Methanol Sparingly soluble 
0.1N HCl Soluble 
0.1 N NaOH Soluble 
Phosphate buffer (pH 6.8) Soluble 
Phosphate buffer (pH 7.4) Soluble 
Acetone Practically insoluble 
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8.1.3.2. Determination of absorption maximum in pH 6.8 phosphate buffer:     
                The absorption maximum of lamivudine was found to be 271.5 nm.
 
Figure 8.3: λ max observed for lamivudine in pH 6.8 phosphate buffer. 
8.1.3.3. Preparation of standard curve of lamivudine in 0.1 N HCl: 
UV absorption spectrum of lamivudine in 0.1N HCl showed λ max at 281 nm. 
Absorbance obtained for various concentrations of lamivudine in 0.1N HCl are given 
in Table 8.3. The curve of absorbance versus concentration for lamivudine was found 
to be linear in the concentration range of 5–30 μg/ ml. The drug obeys Beer- 
Lambert‟s law in the range of 5–30 μg/ ml. 
Table 8.3: Concentration and absorbance of lamivudine 0.1N HCl 
S. No. Concentration (µg/ml) Absorbance 
1 0 0.000 
2 5 0.304 
3 10 0.597 
4 15 0.901 
5 20 1.173 
6 25 1.472 
7 30 1.760 
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Figure 8.4: Calibration curve of lamivudine in 0.1N HCl 
Table 8.4: Calibration parameter values in 0.1 N HCl 
S. No. Parameters  Values  
1 Correlation coefficient (r) 0.9999 
2 Slope (m)  0.0585 
3 Intercept (c) 0.0090 
 
8.1.3.4. Preparation of standard curve of lamivudine in pH 6.8 phosphate buffer: 
UV absorption spectrum of lamivudine in pH 6.8 showed λ max at 271.5 nm. 
Absorbance obtained for various concentrations of lamivudine in pH 6.8 are given in 
Table 8.5. The curve of absorbance versus concentration for lamivudine was found to 
be linear in the concentration range of 5–30 μg/ ml. The drug obeys Beer- Lambert‟s 
law in the range of 5–30 μg/ ml. 
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Table 8.5: Concentration and absorbance of lamivudine in pH 6.8 phosphate buffer 
S. No. Concentration (µg/ml) Absorbance 
1 0 0.000 
2 5 0.210 
3 10 0.409 
4 15 0.592 
5 20 0.788 
6 25 0.981 
7 30 1.183 
 
 
     Figure 8.5: Calibration curve of lamivudine in pH 6.8 phosphate buffer 
Table 8.6: Calibration parameter values in pH 6.8 phosphate buffer 
S. No. Parameters  Values  
1 Correlation coefficient (r) 0.9999 
2 Slope (m)  0.0391 
3 Intercept (c) 0.0086 
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8.1.3.5. Percentage purity of drug: 
The percentage purity of drug was calculated by using calibration curve 
method. The percentage purity of drug was found in official limits. 
Table 8.7: Percentage purity of lamivudine in pure drug 
The reported percentage purity for lamivudine in IP 2007 is 97 to 102%. 
8.1.4. Compatibility testing of drug with polymer: 
  Compatibility of drug and polymers was found to be as following methods 
such as Fourier transform infrared spectroscopy and differential scanning calorimetry. 
8.1.4.1. Fourier transform infrared spectroscopy: 
The FTIR spectrums of lamivudine with different polymers used in 
formulation are shown in Figures 8.6, 8.7, 8.8 and Table 8.8. 
 
 
 
 
 
 
 
 
 
S. No. Percentage purity (%) 
Average percentage  
purity (%) 
1 99.79  
100.13 ± 0.30 2 100.29 
3 100.33 
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Figure 8.6: FTIR spectrum of lamivudine + HPMC K4M 
 
 
Figure 8.7: FTIR spectrum of lamivudine + methyl cellulose 
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Figure 8.8: FTIR spectrum of lamivudine + ethyl cellulose 
Table 8.8: FTIR peak observed for lamivudine with different polymers used in                
                formulations. 
Functional groups 
Peaks observed [Wave No. (cm
-1
)]   
LAM + 
HPMC K4M 
LAM + 
Methyl 
cellulose 
LAM + Ethyl 
cellulose 
O-H stretching 3328.23 3328.23 3328.23 
N-H stretching 3076.51 3076.51 3076.51 
C-H stretching 2838.30 2837.34 2849.87 
C=O stretching 1651.09 1651.09 1655.92 
C=N stretching 1613.48 1613.48 1612.52 
C=C stretching 1521.86 1521.86 1522.83 
C-N stretching 1286.54 1286.54 1286.54 
C-O stretching 1088.84 1088.84 1088.84 
C-C stretching 852.55 851.59 852.55 
C-S stretching 786.97 786.97 786.97 
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According to Table 8.1 and 8.8 and Figures 8.1, 8.6, 8.7 and 8.8, FTIR 
spectrum showed that there was no major difference in peak when compared between 
pure drug of lamivudine and lamivudine with different polymers. Therefore it could 
indicate that there was no incompatibility between drug and different polymers. 
8.1.4.2. Differential scanning calorimetry: 
The compatibility and interactions between drug and polymers were checked 
using differential scanning calorimetry and the results were shown in Figures 8.9, 
8.10, 8.11 and 8.12. 
 
 
Figure 8.9: DSC thermal analysis of lamivudine 
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Figure 8.10: DSC thermal analysis of lamivudine + HPMC K4M 
 
 
Figure 8.11: DSC thermal analysis of lamivudine + methyl cellulose 
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Figure 8.12: DSC thermal analysis of lamivudine + ethyl cellulose 
According to Figures 8.9 to 8.12 and Table 8.9, DSC thermogram showed that 
there was no major difference in onset temperature, end set temperature and peak 
temperature when compared with pure drug thermogram. Therefore it could indicate 
that there was no incompatibility between drug and different polymers. 
Table 8.9: DSC thermogram parameters of lamivudine with various polymers 
S. No. DSC thermogram 
Onset 
temperature 
(°C) 
Peak 
temperature 
(°C) 
End set 
temperature 
(°C) 
1 Lamivudine 172.24 174.17 180.30 
2 
Lamivudine + 
HPMC K4M 
170.70 173.70 176.85 
3 
Lamivudine + 
Methylcellulose 
169.59 172.16 174.04 
4 
Lamivudine + 
Ethylcellulose 
169.75 172.72 174.59 
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8.2. Evaluation of powder blends: 
The blended powders of different formulations were evaluated for angle of 
repose, loose bulk density, tapped bulk density, compressibility index and Hausner 
ratio. The results of these evaluations were as follows: - 
8.2.1. Angle of repose: 
            Angle of repose ranged from 21.48
°
± 0.17 to 23.93
°
± 0.77. The results were 
found to be below 25
o 
and hence the blend was found to have excellent flowability. 
(Table No. 8.10). 
 8.2.2. Loose bulk density and tapped bulk density: 
            Bulk and tapped densities are used for the measurement of Compressibility 
index. The LBD and TBD ranged from 0.455 ± 0.00 to 0.500 ± 0.00 g/ml; and 0.526 ± 
0.00 to 0.556 ± 0.00 g/ml respectively. (Table No. 8.10). 
Table 8.10: Flow characteristics of powder blends 
Formulation 
code 
Angle of 
repose (
o
)* 
Loose bulk 
density 
(g/ml)* 
Tapped 
bulk density 
(g/ml)* 
Hausner 
ratio* 
Carr’s 
index (%)* 
LF1 22.19±0.98 0.455±0.00 0.526±0.00 1.16±0.00 13.636±0.00 
LF2 21.48±0.17 0.500±0.00 0.556±0.00 1.11±0.00 10.000±0.00 
LF3 22.36±0.98 0.500±0.00 0.556±0.00 1.11±0.00 10.000±0.00 
LF4 23.44±0.73 0.455±0.00 0.526±0.00 1.16±0.00 13.636±0.00 
LF5 23.05±0.19 0.476±0.00 0.556±0.00 1.17±0.00 14.286±0.00 
LF6 22.30±0.17 0.455±0.00 0.526±0.00 1.16±0.00 13.636±0.00 
LF7 23.93±0.77 0.476±0.00 0.556±0.00 1.17±0.00 14.286±0.00 
LF8 23.20±0.61 0.455±0.00 0.526±0.00 1.16±0.00 13.636±0.00 
LF9 22.49±0.36 0.455±0.00 0.526±0.00 1.16±0.00 13.636±0.00 
*All the values were expressed as mean± SD, n=3 
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8.2.3. Compressibility index (Carr’s index): 
 The compressibility index (%) ranged from 10.000 ± 0.00 to 14.286 ± 0.00 
(Table No.8.10). The blend was found to have excellent flowing property as the result 
were found to be below 15%.  
 8.2.4. Hausner ratio: 
The Hausner ratio ranged from 1.11 ± 0.00 to 1.17 ± 0.00, (Table No.8.10). 
The result indicates the free flowing properties of the powders. 
8.3. Evaluation of sustained release matrix tablets: 
8.3.1. Appearance: 
Surface nature of tablets was observed visually and it was concluded they did 
not show any defects such as capping, chipping and lamination.  
8.3.2. Physico-chemical characteristics:  
The physical characteristics of lamivudine matrix tablets (LF1 toLF9) such as 
thickness, diameter, hardness, friability, weight variation and drug content were 
determined and the results were shown in table 8.11. 
8.3.2.1. Dimension (Thickness and Diameter): 
 The size (diameter) of the tablets was found to be in the range from 
11.17±0.01 mm to 11.2 ± 0.01 and thickness ranged between 4.46 ± 0.05 to 4.55 ± 
0.07 mm. 
8.3.2.2. Tablet hardness:  
 The hardness of tablets was found to be in the range from 7.35 ± 0.67 kg/cm
2 
to 8.10 ± 0.39 kg/cm
2
. This indicates good mechanical strength of tablet. 
8.3.2.3. Percent friability: 
Percentage friability of all the formulations was found to be in the range from 
0.050 to 0.150 %. This indicates good handling property of the prepared matrix tablet. 
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Table 8.11: Physico-chemical parameters of lamivudine matrix tablets  
F. 
Code 
Dimension 
Hardness 
(kg/cm
2
)* 
Friability 
(%) 
Weight 
variation 
(mg) 
Drug 
content 
(%w/w)**
 
Diameter 
(mm)* 
Thickness 
(mm)* 
LF1 11.20±0.01 4.55±0.07 8.05±0.44 0.150 400.40±1.50 99.87±0.28 
LF2 11.19±0.02 4.46±0.07 7.95±0.37 0.099 402.15±2.94 98.48±0.52 
LF3 11.20±0.01 4.50±0.07 8.10±0.39 0.050 400.90±2.73 99.11±0.53 
LF4 11.19±0.01 4.46±0.05 7.75±0.42 0.075 401.25±3.57 99.45±0.92 
LF5 11.17±0.01 4.49±0.06 8.05±0.44 0.124 402.20±3.61 100.08±0.45 
LF6 11.17±0.04 4.52±0.04 8.00±0.58 0.100 401.75±2.22 99.40±0.31 
LF7 11.19±0.01 4.54±0.10 7.55±0.55 0.087 400.80±3.24 100.15±0.43 
LF8 11.19±0.01 4.49±0.07 7.35±0.67 0.050 403.05±3.12 100.90±0.45 
LF9 11.18±0.01 4.51±0.06 8.05±0.44 0.100 402.95±2.28 98.93±0.86 
*All the values were expressed as mean ± SD, n=10; **All the values were expressed 
as mean ± SD, n=3. 
8.3.2.4. Weight variation: 
A tablet is designed to contain a specific amount of drug. When the average 
weight of the tablet is 400 mg, the pharmacopoeial limit for percentage deviation is ± 
5%. The percentage deviation from average tablet weight for all the tablet was found 
to be within the specified limits and hence all formulations complied with the test for 
weight variation according to the pharmacopoeial specifications IP 2007. 
8.3.2.5. Drug content: 
 The drug content of all the formulation was found to be in the range from 
98.48 ± 0.52 to 100.90 ± 0.45 % w/w, which was within the specified limit as per IP 
2007. 
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8.3.3. In vitro dissolution studies: 
Table 8.12: Dissolution profile of formulation LF1 
Time (hours) 
Percentage 
drug released*
 Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 14.38±0.58 28.76 7.24 0.50 
2 29.43±0.64 58.86 14.61 1.01 
3 33.56±0.53 67.11 20.18 1.18 
4 37.55±1.31 75.10 23.98 1.45 
5 49.49±1.35 98.98 27.90 2.19 
6 54.33±0.92 108.70 31.93 2.48 
7 64.69±0.82 129.40 35.89 3.12 
8 69.65±0.58 139.30 39.81 3.43 
9 74.90±1.06 149.80 43.43 3.79 
10 78.44±0.92 156.90 46.78 4.06 
11 86.73±0.69 173.50 50.03 4.62 
12 92.56±1.85 185.10 53.30 5.07 
*All values were expressed as mean ±SD, n=3. 
 
 
Figure 8.13: In vitro drug release profile of formulation LF1 
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  Table 8.13: Dissolution profile of formulation LF2 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 12.69±0.69 25.38 6.33 0.50 
2 25.17±0.69 50.35 12.63 1.00 
3 29.45±0.82 58.9 17.53 1.21 
4 36.24±0.63 72.49 21.38 1.65 
5 42.96±0.86 85.93 25.04 2.09 
6 48.45±0.88 96.91 28.49 2.47 
7 53.98±0.82 108.00 31.75 2.89 
8 58.17±1.05 116.30 34.81 3.23 
9 67.34±0.82 134.70 37.95 3.95 
10 78.63±0.47 157.30 41.48 4.74 
11 81.05±0.52 162.10 44.98 4.90 
12 89.57±0.63 179.10 48.33 5.51 
*All values were expressed as mean ±SD, n=3. 
 
 
Figure 8.14: In vitro drug release profile of formulation LF2 
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Table 8.14: Dissolution profile of formulation LF3 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 11.25±0.39 22.51 5.77 0.50 
2 20.43±0.50 40.86 10.83 0.93 
3 26.57±0.86 53.14 15.00 1.30 
4 32.41±0.87 64.81 18.60 1.70 
5 37.59±0.81 75.18 21.88 2.09 
6 43.42±0.70 86.85 24.99 2.56 
7 47.57±0.69 95.14 27.94 2.90 
8 49.99±0.47 99.98 30.56 3.12 
9 59.28±0.70 118.60 33.26 3.97 
10 67.88±1.04 135.80 36.31 4.66 
11 72.33±0.59 144.70 39.40 5.03 
12 81.28±1.23 162.60 42.54 5.74 
*All values were expressed as mean ±SD, n=3. 
 
 
Figure 8.15: In vitro drug release profile of formulation LF3 
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Table 8.15: Dissolution profile of formulation LF4 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 16.12±0.49 32.25 8.45 0.50 
2 31.25±0.67 62.50 16.25 0.96 
3 35.25±0.63 70.49 21.90 1.14 
4 39.51±0.63 79.02 25.78 1.40 
5 47.42±0.82 94.83 29.34 1.92 
6 56.21±0.47 112.40 33.13 2.48 
7 66.57±0.86 133.10 37.21 3.11 
8 71.33±0.76 142.70 41.23 3.41 
9 79.63±0.98 159.30 45.06 3.90 
10 83.24±0.78 166.50 48.71 4.17 
11 89.95±0.92 179.90 52.16 4.61 
12 96.63±1.05 193.30 55.59 5.11 
*All values were expressed as mean ±SD, n=3. 
 
 
Figure 8.16: In vitro drug release profile of formulation LF4 
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Table 8.16: Dissolution profile of formulation LF5 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 14.18±0.42 28.35 7.34 0.50 
2 28.45±0.46 56.91 14.43 0.98 
3 32.14±0.77 64.27 19.69 1.16 
4 37.86±0.63 75.71 23.49 1.51 
5 45.69±0.47 91.38 27.11 2.02 
6 51.68±0.98 103.40 30.70 2.43 
7 62.77±0.70 125.50 34.49 3.16 
8 67.34±0.69 134.70 38.33 3.46 
9 74.60±0.78 149.20 41.97 3.94 
10 80.59±0.81 161.20 45.55 4.36 
11 86.23±0.54 172.50 49.00 4.76 
12 93.52±0.63 187.00 52.42 5.29 
*All values were expressed as mean ±SD, n=3. 
 
 
              Figure 8.17: In vitro drug release profile of formulation LF5 
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Table 8.17: Dissolution profile of formulation LF6 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 13.05±0.42 25.38 6.78 0.50 
2 25.84±0.41 50.35 13.14 0.97 
3 29.68±0.70 58.90 17.92 1.18 
4 35.44±0.58 72.49 21.58 1.57 
5 44.08±0.58 85.93 25.22 2.14 
6 48.53±0.42 96.91 28.71 2.43 
7 55.75±1.11 108.00 32.01 2.95 
8 61.62±1.15 116.30 35.30 3.40 
9 66.77±0.40 134.70 38.48 3.79 
10 76.98±0.83 157.30 41.80 4.57 
11 82.70±0.59 162.10 45.26 4.97 
12 89.95±0.82 179.10 48.67 5.49 
*All values were expressed as mean ±SD, n=3. 
 
 
Figure 8.18: In vitro drug release profile of formulation LF6 
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Table 8.18: Dissolution profile of formulation LF7 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 14.59±0.77 29.17 7.29 0.50 
2 29.79±0.85 59.58 14.68 1.01 
3 33.98±0.52 67.96 20.33 1.19 
4 38.55±0.82 77.10 24.30 1.49 
5 46.57±0.64 93.14 27.98 2.00 
6 55.67±0.76 111.30 31.85 2.57 
7 65.46±1.10 130.90 35.96 3.15 
8 70.22±0.29 140.40 39.96 3.46 
9 76.44±1.16 152.90 43.68 3.86 
10 82.39±0.23 164.80 47.25 4.25 
11 88.65±0.75 177.30 50.72 4.71 
12 94.71±0.81 189.40 54.14 5.15 
*All values were expressed as mean ±SD, n=3. 
 
 
Figure 8.19: In vitro drug release profile of formulation LF7 
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Table 8.19: Dissolution profile of formulation LF8 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 13.38±0.31 26.76 6.78 0.50 
2 26.89±0.74 53.78 13.47 0.99 
3 32.29±0.92 64.58 18.83 1.26 
4 37.09±0.44 74.18 22.79 1.53 
5 44.58±0.75 89.15 26.40 2.04 
6 50.26±0.92 100.50 29.92 2.44 
7 57.36±0.52 114.70 33.34 2.93 
8 62.66±0.58 125.30 36.65 3.30 
9 69.18±0.98 138.40 39.88 3.80 
10 79.32±1.11 158.60 43.31 4.54 
11 85.88±0.58 171.80 46.88 4.98 
12 91.26±0.98 182.50 50.36 5.40 
*All values were expressed as mean ±SD, n=3. 
 
 
Figure 8.20: In vitro drug release profile of formulation LF8 
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Table 8.20: Dissolution profile of formulation LF9 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 12.15±0.15 24.30 6.18 0.50 
2 24.92±0.50 49.83 12.38 1.00 
3 28.41±1.05 56.83 17.11 1.19 
4 34.52±0.69 69.03 20.69 1.60 
5 43.42±0.82 86.85 24.37 2.21 
6 47.69±0.75 95.37 27.93 2.49 
7 54.75±1.02 109.50 31.24 2.99 
8 60.43±0.78 120.90 34.51 3.42 
9 64.27±0.59 128.50 37.60 3.73 
10 75.48±0.58 151.00 40.82 4.60 
11 81.66±0.69 163.30 44.26 5.03 
12 86.92±0.70 173.80 47.60 5.44 
*All values were expressed as mean ±SD, n=3. 
 
 
Figure 8.21: In vitro drug release profile of formulation LF9 
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Figure 8.22: In vitro drug release profile of formulations containing HPMC 
K4M polymer. 
 
 
             Figure 8.23: In vitro drug release profile of formulations containing 
methylcellulose polymer. 
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Figure 8.24: In vitro Drug Release profile of formulations containing 
ethylcellulose polymer. 
 
 
 
Figure 8.25: In vitro drug release profile for different polymers at 10% 
                                concentration. 
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             Figure 8.26: In vitro drug release profile for different polymers at 20% 
concentration. 
 
 
              Figure 8.27: In vitro drug release profile for different polymers at 30% 
concentration. 
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Figure 8.28: In vitro drug release profile of LF1 to LF9. 
 
Table 8.21: Time of in vitro drug release for lamivudine t50% values of LF1 to LF9. 
Formulation code 
Time of drug release 
(hours) (t50%) 
LF1 5.2 
LF2 6.3 
LF3 8.0 
LF4 5.3 
LF5 5.8 
LF6 6.2 
LF7 5.3 
LF8 6.0 
LF9 6.4 
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 Figure 8.29: In vitro drug release for t50% values of LF1 to LF9. 
  
Lamivudine drug was soluble in phosphate buffers and its release from the 
matrix was largely dependent on the polymer swelling, drug diffusion and matrix 
erosion. The concentration of polymer in the matrix tablet was a key factor in 
sustaining the drug release. 
Various sustained release formulations were formulated with HPMC K4M, 
methyl cellulose and ethyl cellulose polymer alone; polyvinyl pyrrolidone as binder 
and microcrystalline cellulose was used as diluents. 
The variation in drug release was due to different types of polymers and 
different concentrations of polymer in all the nine formulations. It is expected that the 
developed formulations should have the following theoretical drug release profile. 
The drug released from formulation LF1 to LF3 containing HPMC K4M at 
three concentration levels of 10%, 20%, 30% were found to be 92.56 ± 1.85, 89.57 ± 
0.63, and 81.28 ± 1.23% for lamivudine respectively at the end of 12 hours. It was 
shown in Tables (8.12, 8.13 and 8.14). 
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The drug released from formulation LF4 to LF6 containing methyl cellulose at 
three concentration levels of 10%, 20%, 30% were found to be 96.63 ± 1.05, 93.52 ± 
0.63 and 89.95 ± 0.82% for lamivudine respectively at the end of 12 hours . It was 
shown in Tables (8.15, 8.16 and 8.17). 
The drug released from formulation LF7 to LF9 containing ethyl cellulose at 
three concentration levels of 10%, 20%, 30% were found to be 94.71 ± 0.81, 91.26 ± 
0.98 and 86.92 ± 0.70% for lamivudine respectively at the end of 12 hours. It was 
shown in Tables (8.18, 8.19 and 8.20). 
The drug release rate from HPMC K4M matrix was found to be less as 
compared to methyl cellulose and ethyl cellulose; it was shown in Figure 8.22. This 
might be due to slow hydration of matrix and its property to form a thick gel layer, it‟s 
due to slow erosion of matrix and its property which retard the drug release from the 
tablet for long duration.  
 The overall release rate of lamivudine from methylcellulose and ethylcellulose 
matrices are significantly higher than that from HPMC K4M matrices were shown in 
Figure 8.28 and which is confirmed by smaller MDT (5.11, 5.29, 5.49 and 5.15, 5.40, 
5.44) respectively for methylcellulose and ethylcellulose and higher MDT for HPMC 
K4M matrices. These results are indicating that HPMC K4M has higher drug 
retarding ability for long duration than ethylcellulose and methylcellulose. HPMC 
K4M also showed the least %DE while ethylcellulose and methylcellulose also 
showed the greatest %DE among the tablets with just one of the retarding polymers.  
 The result of t50% was shown in Table 8.21 and Figure 8.29, according to the 
time of drug release values of t50%, the formulation LF3 was selected as the best 
formulation. 
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            In addition to concentration of polymer, the type and viscosity of polymer also 
influences drug release. When drug release data obtained from dissolution study of 
different polymers at 10%, 20% and 30% concentration is plotted against time 
(Figures 8.25, 8.26 and 8.27) respectively, it was observed that low concentration of 
polymer induces more drug release. High concentration of polymer should be 
retarding the drug release for longer period of time.  
           The comparative effect of the drug and polymers on the release profile from 
the formulation and comparing the MDT, %DE and t50% of tablets showed the 
formulation containing HPMC K4M release the drug for longer period of time 
compared to ethylcellulose and methylcellulose. From the above study, the 
formulation LF3 was concluded as the best formulation among all the nine 
formulation of this series. Hence the formulation LF3 was selected for further stability 
study.   
8.3.4. Kinetics of in vitro drug release:  
            In order to investigate the release mechanism, the data were fitted to models 
representing first order, zero order, higuchi and korsmeyer- Peppas. The linear 
regression analysis shown as „r‟ values in Table 8.22, demonstrated that all the 
formulated tablets follows korsmeyer- Peppas release kinetics. The result obtained 
was shown in Figures 8.30 to 8.38. 
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Table 8.22: Different kinetic models for lamivudine matrix tablets (LF1 to LF9) 
F. 
Code 
Zero 
order 
First 
order 
Higuchi Korsemeyer- Peppas Best fit 
model 
R
2
 R
2
 R
2
 R
2
 n 
LF1 0.978 0.918 0.970 0.987 0.720 Peppas 
LF2 0.988 0.895 0.950 0.989 0.749 Peppas 
LF3 0.988 0.927 0.945 0.992 0.759 Peppas 
LF4 0.981 0.849 0.967 0.986 0.698 Peppas 
LF5 0.986 0.890 0.962 0.989 0.731 Peppas 
LF6 0.989 0.899 0.955 0.990 0.743 Peppas 
LF7 0.983 0.888 0.967 0.987 0.726 Peppas 
LF8 0.988 0.892 0.957 0.989 0.736 Peppas 
LF9 0.989 0.922 0.955 0.990 0.759 Peppas 
 
 
 
Figure 8.30: Best fit model (Peppas) of formulation LF1 
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Figure 8.31: Best fit model (Peppas) of formulation LF2 
 
 
 
Figure 8.32: Best fit model (Peppas) of formulation LF3 
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Figure 8.33: Best fit model (Peppas) of formulation LF4 
 
 
 
Figure 8.34: Best fit model (Peppas) of formulation LF5 
 
 
 
 
 
R² = 0.986 
0
0.5
1
1.5
2
2.5
0 0.2 0.4 0.6 0.8 1 1.2
lo
g
 %
 d
ru
g
 r
el
ea
se
 
log time 
 
R² = 0.989 
0
0.5
1
1.5
2
2.5
0 0.2 0.4 0.6 0.8 1 1.2
lo
g
 %
 d
ru
g
 r
el
ea
se
 
log time 
Lamivudine Sustained Release Matrix Tablets               RESULTS AND DISCUSSION 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur.  123 
 
 
 
Figure 8.35: Best fit model (Peppas) of formulation LF6 
 
 
 
Figure 8.36: Best fit model (Peppas) of formulation LF7 
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Figure 8.37: Best fit model (Peppas) of formulation LF8 
 
 
 
Figure 8.38: Best fit model (Peppas) of formulation LF9 
 
 Further, to understand the drug release mechanism, the data were fitted to 
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was observed that almost all the formulated tablets followed anomalous diffusion 
mechanism, which indicates the drug release through diffusion coupled with erosion.   
8.4. Stability study: 
After exposure to accelerated stability conditions the formulation was 
analyzed for various evaluation parameters; results were shown in Table 8.23 and 
Figures 8.39, 8.40 and 8.41.  
Table 8.23: Stability studies of best formulation (LF3) 
Characteristic Initial 1
st
 Month 2
nd
 Month 3
rd
 Month 
Hardness (kg/cm
2
)* 08.10±0.39 08.00±0.50 07.83±0.29 07.67±0.29 
Drug content (%)* 99.11±0.53 99.01±0.44 98.92±0.39 98.76±0.56 
In vitro drug release at 
the end of 12  hours* 
81.28±1.23 81.20±0.96 81.12±0.76 81.09±0.54 
*All the values were expressed as mean± S.D., n=3. 
 
Figure 8.39: Comparison for hardness before and after stability studies of best      
                      formulation LF3. 
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Figure 8.40: Comparisons for drug content of before and after stability studies of best                
 formulation LF3.  
  
Figure 8.41: Comparisons for in vitro drug release profile of before and after stability  
 studies of best formulation LF3. 
From the above studies there was no significance differences was initiate 
between the evaluated data from initial and after stability studies and all the values 
were found in worth accepting limits. The best formulation was showed           
adequate physical stability at 40
o
C ± 2
o
C at 75% ± 5% relative humidity.  
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9. SUMMARY AND CONCLUSION 
             
               Oral route has been the commonly adopted and most convenient route for the 
drug delivery. Oral route of administration has been received more attention in the 
pharmaceutical field because of the more flexibility in the designing of dosage form 
than drug delivery design for other routes. The oral route of delivery is perhaps the 
least invasive method of delivering drugs, it‟s a route that the patient understand and 
accepts, patient are able to administer the medicine to themselves. For the 
manufacturer, solid oral dosage form offer many advantages; are generally the most 
stable forms of drugs, are compact and their appearance can be modified to create 
brand identification. 
            Lamivudine was chosen as a drug having soluble in intestinal pH. Lamivudine 
plays a major role in treatment of HIV infection. It acts as a nucleoside reverse 
transcriptase inhibitor. The drug half-life in plasma is 6 hours. It is bound to plasma 
proteins less than 36%. Lamivudine is rapidly absorbed with a bioavailability of over 
80% following oral ingestion, hence it was considered as an good candidate for the 
design of oral sustained release dosage form.   
           In the present study, an attempt was made to formulate the oral sustained 
release matrix tablets of lamivudine to provide a dosage form for prolonged period of 
time, in order to improve efficacy, reduce the frequency of total dose and better 
patient compliance. Infrared spectroscopy and differential scanning calorimetric 
analysis confirmed the absence of any drug polymer interaction. 
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              The sustained release matrix tablets were prepared by the direct compression 
method using different polymers like hydroxypropyl methylcellulose, methylcellulose 
and ethylcellulose as release retardant polymers. The powders were evaluated for 
angle of repose, bulk density, compressibility index and hausner‟s ratio. All the tests 
revealed that powders showed excellent flow properties. 
           The resulting monolithic tablets were evaluated for thickness, diameter, weight 
variation test, hardness, friability and drug content. All the tablet formulations showed 
acceptable pharmacotechnical properties and complied with pharmacopoeial 
standards. The in vitro release profiles from tablets of drug and different polymer ratio 
were applied on various kinetic models. In vitro release studies revealed that the 
release rate was decreased with increase in polymer proportion.  
            In the present studies, matrix formulation LF3 containing HPMC K4M were 
probably showing maximum retardation of drug release and it shows anomalous 
diffusion mechanism, for these reasons, it was considered that the formulation LF3 as 
best formulation among all the nine formulations. Based on release exponent (n) 
values, it was concluded that mechanism of drug release was found to be diffusion 
coupled with erosion (anomalous transport mechanism).  
From the stability studies, there was no significance difference in hardness, 
drug content and in vitro release profile for the best formulation. 
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10.  FUTURE PROSPECTS 
 
     In the present work, the sustained release matrix tablets of lamivudine were 
prepared by direct compression technique using synthetic polymers like 
hydroxypropyl methylcellulose, methylcellulose and ethylcellulose as release 
retardant polymers. 
 In this work, only physiochemical characterization such as angle of repose, 
Carr‟s index, hausner ratio, weight variation, hardness, thickness, friability, drug 
content and in vitro evaluation of matrix tablet of lamivudine was performed. Along 
with in vitro studies, in vivo studies of drug is most important. 
In future in vivo studies are required to set the in vitro - in vivo            
correlation (IVIVC) which is necessary for development of successful         
formulation and also long term stability studies are necessary.
  
 
 
 
 
 
BIBLIOGRAPHY 
 
 
 
 
 
 
Lamivudine Sustained Release Matrix Tablets                                   BIBLIOGRAPHY 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur.  130 
 
11. BIBLIOGRAPHY 
 
1) Ahmed A. and Sfar Souad. Effect of Viscosity Grades of Ethylcellulose on 
the Sustained Release Properties of Indomethacin from its Tablets Matrix, 
Afr. J.  Pharm.  Pharmacol., 2008, 2(8), 153-156. 
2) Althaf A.S. and Seshadri T. Design and Study of Lamivudine Oral Sustained 
Release Tablets, Pelagia Research Library, 2010, 1(2), 61-76.  
3) Amelia Avachat and Vikram Kotwal. Design and Evaluation of Matrix-Based 
Controlled Release Tablets of Diclofenac Sodium and Chondroitin Sulphate, 
AAPS Pharm. Sci. Tech., 2007, 8(4), 1-6. 
4) Anonymous, http://www.biog1105-1106.org 
5) Anonymous, http://www.emedicinehealth.com 
6) Anonymous, http:// en.wikipedia.org/wiki/Lamivudine 
7) Anonymous, http://www.medicinenet.com 
8) Anonymous, http://www.nlm.nih.gov/medlineplus/druginfo/meds.html 
9) Anonymous, http://www.methocel.com 
10) Anonymous, http://www.pharmainfo.net 
11) Anonymous, http://www.rxlist.com/epivir-drug.htm 
12) Anonymous, http://www.who.int 
13) Anonymous, Indian Pharmacopoeia. Government of India Ministry of Health 
and Family Welfare, Vol-I, II and III, The Indian Pharmacopoeia 
Commission, Ghaziabad, India, 2007, 142-183, 1276-1285.  
Lamivudine Sustained Release Matrix Tablets                                   BIBLIOGRAPHY 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur.  131 
 
14) Ansel H.C., Allen L.V. and Popovich N.G. Pharmaceutical Dosage Forms 
and Drug Delivery System, 4
th
 edn., Lippincott Williams and Wilkins, New 
Delhi, 2009, 227-274. 
15) Ashok Kumar P., Pranitha Yeluri and Ranjit Kumar P. Formulation and in- 
vitro Evaluation of Controlled Release Matrix Tablet of Lamivudine, Journal 
of Global Pharma Technology, 2010, 2(7), 52-59.  
16) Aulton M.E. Pharmaceutics: The Design and Manufacture of Medicine, 3rd 
edn., Churchill Livingstone, New York, 2007, 355-359,483-498.  
17) Bandhalarajan S., Shanmugam S. and Vetrichelvan T. Formulation and 
Evaluation of Sustained Release Matrix Tablet of Zidovudine Using Different 
Polymers, Research Journal of Pharmaceutical, Biological and Chemical 
Sciences, 2011, 2(1), 576-589.    
18) Banker G.S. and Rhodes C.T. Modern Pharmaceutics, 4th edn., Informa 
Health Care USA, Marcel Dekker, Inc, New York, 2009, 501-514. 
19) Brahmankar D.M. and Jaiswal S.B. Biopharmaceutics and Pharmacokinetics 
A Treatise, 2
nd
 edn., Vallabh Prakashan, New Delhi, 2009, 397-452. 
20) Carstensen J.T. and Rhodes C.T. Drug Stability Principles and Practices, 3rd 
edn., Marcel Dekker, Inc, New York, 2008, 415-481. 
21) Chein Y.W. Novel Drug Delivery System, 2nd edn., Revised and Expanded. 
Marcel Dekker, Inc, New York, 2009, 139-196.  
22) Deepak S. and Rana A.C. Formulation Development of Quetiapine Fumarate 
SR Matrix Tablets, Pelagia Research Library, 2010, 1(1), 48-57. 
23) Elvis M and Deepali G. UV Spectrophotometric Method for Assay of the 
Anti-Retroviral Agent Lamivudine in Active Pharmaceutical Ingredient and 
Lamivudine Sustained Release Matrix Tablets                                   BIBLIOGRAPHY 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur.  132 
 
in its Tablet Formulation, Journal of Young Pharmacists, 2010, 2(4), 417-
419. 
24) Gohel M.C., Parikh R.K. and Padshala M.N. Formulation and Optimization 
of Directly Compressible Isoniazid Modified Release Matrix Tablet, Indian 
Journal of Pharmaceutical Sciences, 2007, 69(5), 640-645. 
25) Goodman and Gilman‟s. The Pharmacological Basis of Therapeutics, 10th 
edn., Harman J.G. and Limbird L.E, New York, 2001, 1349-1359. 
26) Harnish Patel, Dhrupesh R. Panchal and Mayur Suthar. Matrix Type Drug 
Delivery System: A Review, Journal of Pharmaceutical Science and 
Bioscientific Research, 2011, 1(3), 143-151. 
27) Harris Shoaib M., Tazeen J., Merchant H.A. and Yosuf R.I. Evaluation of 
Drug Release Kinetics from Ibuprofen Matrix Tablets Using HPMC, Pak. J. 
Pharm. Sci., 2006, 19(2), 119-124. 
28) Indranil Kumar Yadav and Singh H.P. Formulation, Evaluation and 
Optimization of Aceclofenac Sustained Release Matrix Tablets, International 
Journal of Pharm Tech Research, 2010, 2(1), 592-598. 
29) Kalyani C., and Prabhakar R.V. Formulation and Evaluation of Zidovudine 
Sustained Release Matrix Tablets, J. Pharm. Res., 2009, 2(6), 1031-1034. 
30) Krishna Vamsi Allam and Gannu Praveen Kumar. Controlled and Sustained 
Release Approaches in Developing Suitable Dosage Forms for the Anti-
Retroviral Drug Lamivudine, International Journal of Pharmaceutical 
Sciences Review and Research, 2011, 8(1), 21-27. 
31) Kumar Pal T., Sam Solomon and Senthamil Selvan. Formulation and 
Optimization of Sustained Release Matrix Tablet of Metformin 
Lamivudine Sustained Release Matrix Tablets                                   BIBLIOGRAPHY 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur.  133 
 
Hydrochloride 500mg Using Response Surface Methodology, The 
Pharmaceutical Society of Japan, 2007, 127(8), 1281-1290. 
32) Lachman L., Lieberman H.A. and Kanig J.L. The Theory and Practice of 
Industrial Pharmacy, 4
th
 edn., Varghese Publishing House, Mumbai, 1991, 
88,293-345. 
33) Lieberman H.A., Lachman L. and Schwartz J.B. Pharmaceutical Dosage 
Forms: Tablets Vol-I And III, 2
nd
 edn., Marcell Dekker, New York, 1999, 
131-245, 199-213.   
34) Madhusmruti K., Santanu C., Anuradha S., Debashisha P., Nazia K. and 
Santosh K.P. Development of Propranolol Hcl Matrix Tablets: An 
Investigation on Effects of Combination of Hydrophilic and Hydrophobic 
Matrix Former Using Multiple Compression Analysis, Int. J. Pharm. Sci. Rev 
And Res., 2010, 1(2), 1-7. 
35) Manavalan R. and Ramasamy S. Physical Pharmaceutics, 2nd edn., Vignesh 
Publisher, India, 2001, 288-299. 
36) Patil U.K., Sourabh Jain and Yadav S.K. Preparation and Evaluation of 
Sustained Release Matrix Tablet of Furosemide Using Natural Polymers, 
Research J. Pharm. And Tech., 2008, 374-376. 
37) Potu Apparao, Jyothi and Veerareddy Prabhakar Reddy. Formulation and 
Evaluation of Gum Based Matrix Tablets of Lamivudine, Pelagia Research 
Library, 2011, 2 (3), 176-192. 
38) Prabu Moses, Subramanian L. and Palanichamy S. Formulation and 
Evaluation of Ciprofloxacin Controlled Release Matrix Tablets, Scholars 
Research Library, 2010, 2(2), 237-243. 
Lamivudine Sustained Release Matrix Tablets                                   BIBLIOGRAPHY 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur.  134 
 
39) Raghuram Reddy K., Srinivas M. and Srinivas R. Once Daily Sustained 
Release Matrix Tablets of Nicorandil: Formulation and In Vitro Evaluation, 
AAPS Pharm. Sci. Tech., 2003, 4(4), 1-9. 
40) Raju M., Sundaramoorthy K. and Vetrichelvan T. Formulation and In-Vitro 
Evaluation of Sustained Release Matrix Tablets of Aceclofenac by Using 
Different Natural Polymers, Research Journal of Pharmaceutical, Biological 
and Chemical Sciences, 2010, 1(4), 279-291.   
41) Ranendra Narayan Saha, Punna Rao Ravi and Sindhura Ganga. Design and 
Study of Lamivudine Oral Controlled Release Tablets, AAPS Pharm. Sci. 
Tech., 2007, 8 (4), 1-9. 
42) Ravichandran V., Shalini S. and Shanooja V.P. Application of UV-
Spectrophotometric Methods for Estimation of Lamivudine in Tablets, Digest 
Journal of Nanomaterials  and Biostructures, 2009, 4(2), 357-360. 
43) Raymond C Rowe, Paul J Sheskey and Marian E Quinn. Handbook of 
Pharmaceutical Excipients, 6
th
 edn., London, Pharmaceutical Press, 2009, 
129, 262, 326,404,438, 581, 728. 
44) Saleh M. Al-Saidan, Yellela S. R. Krishnaiah and Srinivas S. Patro. In-Vitro 
and In-Vivo Evaluation of Guar Gum Matrix Tablets for Oral Controlled 
Release of Water-Soluble Diltiazem Hydrochloride, AAPS Pharm. Sci. Tech., 
2005, 6 (1), 1-8. 
45) Sandip B.T., Krishna Murthy T., Raveendra Pai M., Pavak R.M. and Pasula 
B.C. Controlled Release Formulation of Tramadol Hydrochloride Using 
Hydrophilic and Hydrophobic Matrix System, AAPS Pharm Scitech., 2003, 
4(3), 1-7. 
Lamivudine Sustained Release Matrix Tablets                                   BIBLIOGRAPHY 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur.  135 
 
46) Saravanabhavan Shanmugam, Rajappan Manavalan and Devashya 
Venkappayya. Release Kinetics Studies of Aceclofenac from Sustained 
Release Matrix Tablets, Journal of Pharmacy Research, 2010, 3(11), 2725-
2727. 
47) Seema Pushkar and Nikhil K. Sachan. Pharmaceutical Characterization and 
Assessment of Drug Release Behaviour of Diclofenac Sodium Extended 
Release Matrix Devices, Int. J. Pharm. Sci. Tech., 2009, 2(1), 14-21. 
48) Shalin A. Modi, Gaikwad P.D., Bankar V.H. and Pawar S.P. Sustained 
Release Drug Delivery System: A Review, International Journal of Pharma 
Research and Development, 2011, 2(12), 147-160. 
49) Silverstein R.M. and Webster F.S. Spectrometric Identification of Organic 
Compounds, VI 
 
edn., John Wiley and Sons, Inc. USA, 2003, 71-144. 
50) Skoog D.A., Holler F.J. and Crouch S.R. Fundamental of Analytical 
Chemistry, 8
th
 edn., Thomson Asia Pvt. Ltd., Singapore, 2004, 775-781, 811-
819. 
51) Sudha T., Saminathan J. and Kondapalli Anusha. Simultaneous UV- 
Spectrophotometric Estimation of Lamivudine and Abacavir Sulphate in Bulk 
and in Tablet Dosage Form, J. Chem. Pharm. Res., 2010, 2(5), 45-51. 
52) Sundaramoorthy K., Kavimani S. and Swaminathan S. Development and 
Evaluation of Extended Release Metformin Hydrochloride Matrix Tablets: 
Rate of In-Vitro and In-Vivo Release Studies, Journal of Pharmacy Research, 
2011, 4(3), 884-885. 
53) Swati Jain, Neelesh Kumar Mehra and Akhlesh Kumar Singhai. Development 
and Evaluation of Sustained Release Matrix Tablet of Lamivudine, 
Lamivudine Sustained Release Matrix Tablets                                   BIBLIOGRAPHY 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur.  136 
 
International Journal of Pharmaceutical Sciences and Research, 2011, 2(1), 
454-46. 
54) Vyas S.P. and Devyani Dube.  Simultaneous Spectrophotometric Estimation 
of Lamivudine and Silymarin in Mixture, International Journal of Pharmacy 
and Pharmaceutical Sciences, 2009, 1(2), 107-111. 
55) Vyas S.P. and Khar R.K. Controlled Drug Delivery, 1st edn., Vallabh 
Prakashan,  New Delhi, 2002, 1-36, 97-151, 164-170. 
56) Willard H.H., Merritt L.L. and Settle F. A. Instrumental Methods of Analysis, 
12
th
 edn., CBS Publishers and Distributors, New Delhi, 2008, 762-766.
  
 
  
 
 
JOURNAL 
PUBLICATION 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
